

# THE UNIVERSITY OF BRITISH COLUMBIA

## Curriculum Vitae for Faculty Members

**Date:** Jul 1, 2023      **Initials:**

- SURNAME:** Olson      **FIRST NAME:** Robert      **MIDDLE NAME:** Anton
- DEPARTMENT/SCHOOL:** UBC, Surgery, Division of Radiation Oncology and Developmental Radiotherapeutics; affiliate appointment University of Northern British Columbia
- FACULTY:** Medicine, Department of Surgery, Division of Radiation Oncology and Developmental Radiotherapeutics
- PRESENT RANK:** Professor      **SINCE:** July 1, 2023
- POST-SECONDARY EDUCATION**

(a) *Post-Secondary Education*

University or Institution	Degree	Subject Area	Dates
Harvard University	MSc	Epidemiology	Jul 2009 – Aug 2010
University of Calgary	MD	Medicine	Apr 2002 – Apr 2005
University of Calgary	BSc	First Class Honours in Cellular, Molecular, and Microbial Biology	Sep 1998 – Apr 2002

**Title of Dissertation and Name of Supervisor**

**MSc Thesis:** Prospective evaluation of legal difficulties and quality of life in adult survivors of childhood cancer. Supervisors: Dr. Karen Goddard (UBC) and Dr. E. Francis Cook (Harvard)

**BSc Honours Thesis:** Characterization of self-splicing activities of group II introns in *Sinorhizobium* and *E. coli* and investigation of a new tertiary interaction. Supervisor: Dr. Steven Zimmerly

(b) *Continuing Education/Training*

University or Institution	Rank or Title	Detail	Dates
University of British Columbia	Resident	Radiation Oncology	Jul 2005 – Jun 2010

(c) *Continuing Medical Education*

University, Institution or Association	Type	Detail	Dates
UBC	Workshop: Supporting Sexual and Gender Diversity	Workshop targeted at Northern Medical Program Leaders	June 5, 2019
UBC, Educational Primer for Clinicians: Train the Trainer session	Workshop to Train Facilitators of the ABC primer and the Fred Bryans Master Teacher Program	Full Day workshop	Oct 23, 2014
Harvard	In-person course	Principles of Medical Education: Maximizing your teaching skills	Mar 19-22, 2014

Scientist Knowledge Translation Training, UNBC	Educational Workshop	Knowledge translation workshop	Sep 27-28, 2012
Rural Health Services Research Network of BC	Educational Workshop	Aboriginal Research Ethics workshop	Jun 15, 2012
PHSA Indigenous Cultural Competency Training Program	Educational workshop	Group-based 8 week online course	Jan 16-Mar 12, 2012
University of British Columbia, DEF Education Primer for Clinicians	Teaching workshop	Three workshops exploring advanced teaching and evaluation methods for clinicians	Apr 15, 2011

(d) Special Professional Qualifications

Fellow of the Royal College of Physicians of Canada - Radiation Oncology, June, 2010  
 Licentiate: College of Physicians and Surgeons of BC, July, 2007  
 Licentiate: Medical Council of Canada, December, 2006

**6. EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of British Columbia	Resident	Jul 2005 – Jun 2010
University of Calgary	Honours & Summer Research Student	Sep 2001 – Aug 2002

(b) *At UBC*

University, Company or Organization	Rank or Title	Dates
UBC, Department of Surgery	Associate Head, Research	July 2021 - Present
UBC, Northern Medical Program	Research Lead	Jan 2018 - Present
UBC, Department of Surgery	Division Head, Radiation Oncology and Developmental Radiotherapeutics	Jan 2017 - Present
BC Cancer - Centre for the North	Department Head, Radiation Oncology	Jun 2016 – Sep 2021
UBC, Northern BC	Director of Faculty Development	Oct 2013 – Dec 2017
University of Northern BC	Affiliate Faculty Member	Jun 2013 - Present
BC Cancer - Centre for the North	Lead, Research and Clinical Trials	May 2013 – Present
BC Cancer - Centre for the North	Radiation Oncologist	Jul 2012 – Present
BC Cancer - Vancouver	Radiation Oncologist	Aug 2010 – Jul 2012

(c) *Date of granting of tenure at UBC:* N/A because of Partner Faculty appointment

**7. LEAVES OF ABSENCE**

University, Company or Organization at which Leave was taken	Type of Leave	Dates
No leaves of absence		

## 8. TEACHING

### (a) *Areas of special interest and accomplishments*

In northern BC, the primary form of teaching is focused on medical students in the UBC Northern Medical Program (NMP). I set up the first selective in Radiation Oncology, and I was the Education Lead in Radiation Oncology for undergraduate medical students until 2018. I continue to teach regularly at the bedside within these programs (over 125 students), with a focus on head and neck examination, management of breast cancer, and palliation of metastatic disease. I teach the ENT clinical skills each year, including an introduction to nasopharyngoscopy, which is consistently given outstanding evaluations. I am also actively involved in case based learning every year, including my selection as one of four teachers for the transition into clinical education course (MEDD 422D; TICE). In addition, I have extensive experience in teaching and supervising students in research methodology, including supervising over 90 trainees in their research projects at multiple levels. As evidence of my ability to connect with and mentor medical students, I have been invited to lead CaRMS interview preparation sessions with the 4<sup>th</sup> year medical students each year since 2015, and I have led a mentorship group of year 1- 4 NMP students since 2012.

I developed the Radiation Oncology Fellowship Program at BC Cancer – Prince George, which was the first formal UBC fellowship program in the entire Northern Health region, and attract Fellows from across Canada and internationally. I was the 1<sup>st</sup> Regional Director of Faculty Development for Northern BC, for the UBC Faculty of Medicine, which includes responsibilities at the undergraduate and postgraduate level until the end of 2017. Furthermore, as the Division Head of Radiation Oncology at UBC, I am responsible for the selection and mentorship of the Radiation Oncology Program Director and Director of Undergraduate Education, both of whom I meet with regularly to guide the education of medical students and resident teaching throughout our province. I also was elected to the Specialty Committee (Western Canada representative) for Radiation Oncology with the Royal College of Physicians and Surgeons of Canada, an attestation to my leadership in teaching nationally. Lastly, as the first Associate Head – Research, in the Department of Surgery at UBC, I work to ensure residents have opportunities for research mentorship in all of the Divisions of Surgery, provincially.

### (b) *Courses Taught*

Date(s)	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2023S	MEDD412	8	32		8		
2023S	MEDD412A	27	8		22		5
2022F	BCMB 401 (UNBC)	1.5	19	1.5			
2022S	MEDD422	2.5	8		2.5		
2022S	MEDD422D	6	8		6		
2022S	MEDD412	8	30		8		
2021F	BCMB 401 (UNBC)	1.5	32	1.5			
2021S	MEDD422	2.5	8		2.5		
2021S	MEDD412A	27	9		22		5
2021S	MEDD412	8	34		8		

<b>2020F</b>	BCMB 401 (UNBC)	1.5	20	1.5			
<b>2020S</b>	MEDD422	2.5	10		2.5		
<b>2020S</b>	MEDD422D	6	8		6		
<b>2020S</b>	MEDD412	8	31		8		
<b>2019F</b>	BCMB 401 (UNBC)	1.5	29	1.5			
<b>2019S</b>	MEDD 431	2	8	2			
<b>2019S</b>	MEDD 422D	8	8		8		
<b>2019S</b>	HHSC 640	2	12	2			
<b>2019S</b>	MEDD 422B	21	8		16		5
<b>2019S</b>	MEDD 412	9	33		8		
<b>2018F</b>	BCMB 401 (UNBC)	1.5	33	1.5			
<b>2018S</b>	MEDD 422 TICE	3	16		16		
<b>2018S</b>	MEDD 422D	8	8		8		
<b>2018S</b>	MEDD 412	8	32		8		
<b>2018S</b>	EBM 4 <sup>th</sup> year	2	29	2			
<b>2017S</b>	MEDD 422D	10	8		8		
<b>2017S</b>	MEDD 422B	21	8		16		5
<b>2017S</b>	HHSC 440 (UNBC)	3	15	3			
<b>2017S</b>	MEDD 412	8	32		8		
<b>2016F</b> Oct 3	BCMB 401 (UNBC)	2	22	2			
<b>2016S</b>	UBC Surgery clerkship	2	12	2			
<b>2016S</b>	MEDD 412	8	32		8		
<b>2015F</b> Oct 23	BCMB 401 (UNBC)	1.5	20	1.5	8		
<b>2015S</b> April 14 & 16, 2015	INDE 410	8	32		8		
<b>2014F</b> Sep 1 - Dec 19, 2014	IDIS 791-3 (UNBC)	39	1	2			
<b>2014F</b> Oct 21, 2014	BCMB 401 (UNBC)	2	20	2			
<b>2014S</b> Jul 31, 2014	UBC surgery clerkship (province wide)	1.5	~50	1.5			
<b>2014S</b> Jun 5, 2014	UBC surgery clerkship (province wide)	1.5	~50	1.5			
<b>2013F</b> Nov 1, 2013	BCMB 401 (UNBC)	2	20	2			
<b>2013W</b> Sep 10, 2013	UBC surgery clerkship (province wide)	2	~50	2			
<b>2013S</b> Jun 18, 2013	UBC NMP Surgery clerkship	2	8	2			
<b>2013S</b> May 28, 2013	UBC NMP Surgery clerkship	2	8	2			
<b>2011W</b> Nov 16, 2011	BCMB 401 (UNBC)	1	20	2			
<b>2010F</b> Nov 17, 2010	HHSC 350 (UNBC)	1	40	1			

**Brief Descriptions of the Principal Courses I Taught:**

**EBM 4<sup>th</sup> Year Session:** I lead the NMP class in a lecture and several small group sessions on evidence based medicine and interpretation of research articles

**MEDD 412 Clinical Skills ENT, Head and Neck:** Teach all ~32 NMP 1<sup>st</sup> year medical students the fundamentals of ENT physical examination each year, including introduction to nasopharyngoscopy

**MEDD 412A Case Based Learning:** CBL Tutor for 4 weeks for year 1 medical students

**MEDD 422D Case Based Learning: Transition into Clinical Practice (TICE):** CBL Tutor for 2 week block at the end of year 2

**MEDD 422B Case Based Learning:** CBL Tutor for 4 week block near end of year 2

**BCMB 401 Basic science of oncology (UNBC):** In this course, I gave a lecture on Radiation Oncology Physics and Biology in 2011, 2013 - 2016.

**IDIS 791-3 Advanced Epidemiology Approaches to Complete Comparative Effectiveness Research (UNBC):** I developed this course for a MSc student completing comparative effectiveness research with me.

**UBC surgery clerkship lectures Radiation Oncology Introduction and Emergencies.** I have given multiple lectures on radiation oncology during the 3<sup>rd</sup> year surgery clerkship, both at the NMP and provincially over videolink.

**HHSC 305 Introduction to Epidemiology (UNBC):** In this course, I gave a lecture on selection bias in clinical studies.

**HHSC 440 Engaging in Health Medical Professionalism (UNBC):** In this course, I gave an overview of oncology interdisciplinary services in BC through case examples

**Clinical Teaching/MD Undergraduate Students Supervised (see teaching dossier for details)**

**MD students = 136 students**

**# of hours = 1,577 hours**

Description	Duration	Number of Students	Year	Total Hours	Student level
<b>Clinical Clerkships</b>					
Surgery (Radiation Oncology)					
	2 weeks	1	2023	8	Year 4
	2 weeks	2	2023	17	Year 3
	2 weeks	1	2022	15	Year 4
	2 weeks	2	2022	27	Year 3
	2 weeks	1	2021	12	Year 4
	2 weeks	4	2021	30	Year 3
	2 weeks	3	2020	17	Year 3
	2 weeks	10	2019	96	Year 3
	2 weeks	10	2018	104	Year 3
	2 weeks	2	2017	32	Year 4
	2 weeks	15	2017	144	Year 3
	2 weeks	4	2016	54	Year 4
	2 weeks	5	2016	73	Year 3
	2 weeks	4	2015	73	Year 4
	2 weeks	7	2015	116	Year 3
	2 weeks	12	2014	201	Year 3

	4 weeks	2	2014	48	Year 4
	2 weeks	12	2013	282	Year 3
	2 weeks	10	2012	41	Year 3
	2 weeks	19	2011	136	Year 3
	2 weeks	9	2010	48	Year 3

### **Clinical Teaching Residents Supervised**

**Residents Total = 17**  
**# of hours = 770**

Description	Duration	Number of Students	Year	Total Hours	Student level
Radiation Oncology Resident (from Ottawa to work with me)	4 weeks	1	2020	60	PGY5
Radiation Oncology Resident	4 weeks	1	2020	60	PGY3
Radiation Oncology Resident	4 weeks	1	2019	50	PGY3
Family Practice Resident	1 week	1	2015	8	PGY1
Radiation Oncology Resident	4 weeks	1	2015	25	PGY3
Radiation Oncology Resident	4 weeks	1	2015	20	PGY5
Radiation Oncology Resident	3 weeks	1	2015	30	PGY3
Family Practice Resident	2 weeks	1	2015	35	PGY2
Radiation Oncology Resident	4 weeks	1	2014	90	PGY4
Radiation Oncology Resident	4 weeks	1	2013	120	PGY5
Visiting Radiation Oncology	2 weeks	1	2012	80	PGY5
Medical Oncology Residents	4 weeks	2	2012	60	PGY5
Radiation Oncology Resident	4 weeks	1	2012	32	PGY3
Radiation Oncology Residents	2 weeks	2	2011	70	PGY2&4
Medical Oncology Resident	3 weeks	1	2011	30	PGY5

### *c) Other Teaching of Undergraduates, Graduates and Postgraduates*

#### **Postgraduate Scheduled Teaching**

Date(s)	Hours	Class Size	Group	Topic
Feb 11, 2022	1	8	Rad Onc Resident	Clinical Trial Design
May 6, 2021	1	6	Rad Onc Resident	SABR for metastases
Nov 12, 2020	1.5	8	Rad Onc Resident	Career Planning/Fellowship Selection
May 21, 2020	1.5	8	Rad Onc Resident	Clinical Trial Design
Mar 7, 2019	1.5	8	Rad Onc Resident	SABR for oligometastases
Dec 13, 2018	1.5	12	FP Residents	Radiation Oncology
May 7, 2015	2	12	FP Residents	Radiation Oncology Emergencies
May 8, 2014	2	8	Rad Onc Residents	Head & Neck Anatomy for Oncology
May 7, 2013	2	16	FP Residents	Radiation Oncology Emergencies
Feb 20, 2013	2	6	Rad Onc Residents	Interpretation of Retrospective Reviews
Dec 6, 2012	2	8	Rad Onc Residents	Critical Appraisal of Journal Articles
May 10, 2012	2	8	Rad Onc Residents	Unknown Primary Head & Neck Cancer
May 10, 2012	2	8	Rad Onc Residents	Head & Neck Cancer RT Treatment Planning
Mar 8, 2012	2	8	Rad Onc Residents	IMRT Physics in Head & Neck Cancer
Aug 4, 2011	2	8	Rad Onc Residents	Survival Analysis using SPSS
Jun 8, 2011	2	10	Rad Onc Residents	Introduction to Head & Neck Oncology
May 26, 2011	4	8	Rad Onc Residents	Practice Oral Presentations for Residents' Day

May 19, 2011	4	4	Rad Onc Residents	Senior Resident Annual Exams
Sep 8, 2010	2	5	Palliative Care Fellows	Radiotherapy for Palliative Care Physicians
Feb 3, 2010	2	10	Rad Onc Residents	Impact of Dose per Fraction in Radiotherapy
Nov 9, 2009	2	10	Rad Onc Residents	Approach to Spinal Cord Compressions
Oct 7, 2009	2	10	Rad Onc Residents	Pelvic Anatomy for the Radiation Oncologist
Sep 9, 2009	3	4	Palliative Care Fellows	The Role of Palliative Radiotherapy
Sep 3, 2009	2	10	Rad Onc Residents	Survival Analysis using SPSS
Aug 27, 2009	2	10	Rad Onc Residents	Tips on Selecting a Project in Residency
Aug 27, 2009	2	10	Rad Onc Residents	Introduction to Epidemiology and Biostatistics

(d) *Research Students Supervised*

### Undergraduate Students Supervised and/or Co-Supervised

<b>Student (UBC unless otherwise stated)</b>	<b>Start Date</b>	<b>End Date</b>
<b>BSc students in honours/research thesis</b>		
Josh Power (UNBC)	Sep 2015	Jun 2016
Emily Yurkowski (UNBC)	May 2014	Aug 2015
Andrew Kiraly (UNBC)	Jan 2013	Jun 2013
Jeffrey Lau	May 2008	Oct 2009
<b>MD Students</b>		
Alex Benny	Jan 2020	Current
Sarah Appleby	Sep 2019	Current
Shayne Hopwood	July 2019	Sep 2019
Emily O'Reilly	July 2019	Current
Deanna Kerrigan	Jan 2019	Apr 2019
Jack Yuan	Jan 2018	Dec 2020
Marco Arimare	Jan 2018	Jun 2018
Kristjan Myting	Mar 2018	Apr 2019
Hamish Frayne	Jun 2018	Sep 2018
Arsh Sidhu	Jun 2018	Sep 2018
Satvir Pandher	Jun 2018	Dec 2018
Christopher Galbraith (UBC)	May 2018	Dec 2020
Jackie Regan (FLEX UBC)	Jan 2017	Apr 2018
Gurkirat Kandola	May 2017	Jun 2018
Neelam Minhas	May 2017	Jun 2018
Chet Stickle (FLEX UBC)	Dec 2016	Apr 2017
Ahsen Chaudry (FLEX UBC)	Sep 2016	Apr 2017
Domnick Manhas (FLEX UBC)	Sep 2016	Dec 2016
Simran Lehal (FLEX UBC)	Jan 2016	Dec 2016
Alexa Dang (FLEX UBC)	Jan 2016	Dec 2016
Linda Yang (FLEX UBC)	Jan 2016	Dec 2016
Adrienne Stedford	Jun 2015	Sep 2015
Scott Matlock	Jun 2015	Aug 2015
Justin Glazier (Royal College of Surgeons in Ireland)	Feb 2015	Mar 2015
Quinn Gentles	Jun 2014	Sep 2014
Kelsey Roden	Jun 2014	Sep 2014
Randi Woodbeck	Jun 2013	Sep 2013
Luke Hughson	Jun 2013	Sep 2013
Dan Le	May 2011	Jan 2012
Gavin Wilson	Jun 2011	Aug 2011
Rehana Manji	Mar 2011	Jul 2011

Vivian Ma	Feb 2010	Jun 2010
Gabe Hung	Jul 2009	Sep 2010
Andrea Lo	Jul 2009	Oct 2009

## Graduate Students or Fellows Supervised and/or Co-Supervised

I developed the fellowship program in Radiation Oncology at the BC Cancer Agency – Centre for the North. I found funding for this program, and subsequently recruited all fellows to come to Prince George for the training. I have also developed a strong graduate program and recruit trainees for MSc positions internationally, with an incoming PhD student for September 2021.

Student Name	Program Type	Year		Principal Supervisor(s)	Co-Supervisor(s)
		Start	Finish		
<b>MSc/PhD Students</b>					
Andrea D'Angelo	MSc, IOP	2020		Robert Olson	Alan Nichol
Hadassah Abraham	MSc (UNBC)	2019	2023	Robert Olson	Dezene Huber
Ling Yan	MSc, IOP	2016	2020	Robert Olson	Alanah Bergman, Joel Singer
Tracy Ann Dattadeen	MSc, IOP	2016	2018	Robert Olson	Fuchsia Howard
Mary McLay	MSc, IOOP	2014	2017	Robert Olson	Russ Callaghan
Allison Walter	Masters (UofA)	2013	2015	Robert Olson	
Manpreet Tiwana	Interdisciplinary Studies (UNBC)	2013	2016	Robert Olson and Sarah de Leeuw	N/A
Ben Lee	Masters of Health Administration (UBC Thesis)	2013	2014	Robert Olson	Helena Daudt
<b>Fellows</b>					
Roel Schlijper	Radiation Oncology Fellow	2018	2020	Robert Olson	Stacy Miller, Boris Valev
Theodora Koulis	Radiation Oncology Fellowship	2016	2017	Robert Olson	Stacy Miller, Boris Valev, Allison Ye
Sonia Lee	Radiation Oncology Fellowship	2015	2016	Robert Olson	Stacy Miller, Boris Valev, Allison Ye
Kwamena Beecham	Radiation Oncology Fellowship	2013	2015	Robert Olson	Stacy Miller, Boris Valev
Manpreet Tiwana	Radiation Oncology Fellowship	2012	2014	Robert Olson	Stacy Miller, Boris Valev
Elisa Chan	Radiation Oncology Fellowship	2012	2012	Hannah Carolan	Mitchell Liu, Robert Olson, Scott Tyldesley
Jeff Cao	Radiation Oncology Fellowship	2011	2012	Scott Tyldesley and Robert Olson	N/A
Matthew Follwell	Radiation Oncology Fellowship	2010	2011	Jon Wu	Eric Berthelet, John Hay, Robert Olson

## Graduate Student Supervisory Committees

Student Name	Program Type	Year		Supervisor	Committee Member
		Start	Finish		



Omolara Odulaja	PhD (UNBC)	2018	2021	Sarah de Leeuw	<b>Robert Olson,</b> Henry Harder, Susan Burke
Alina Schroeder	MA Interdisciplinary Studies (UNBC)	2014	2016	Neil Hanlon	<b>Robert Olson</b>
Mark Barnes	MSc Chemistry (UNBC)	2011	2013	Chow Lee	<b>Robert Olson,</b> Stephen Rader

(e) *Continuing Education Activities*

**1. Activities as presenter/facilitator at CME Courses (UBC and non-UBC)**

1. Apr 20, 2023. *What's new in palliative*. Best of ASTRO 2023. Virtual
2. May 13, 2022. *Mentorship in Department of Surgery*. Department of Surgery Research Retreat. Virtual.
3. Mar 28, 2022. The medical student as a research collaborator: *Clinical Research Opportunities*. Prince George, BC.
4. Feb 9, 2022. Invited speaker at UBC Dep of Surgery Grand Rounds. *Research Vision for the Department of Surgery*.
5. Apr 12, 2019. Increasing research capacity in Northern BC. Jasper Spring Retreat & Medical Conference.
6. Jan 24, 2019. Stereotactic Ablative Radiotherapy for limited metastatic disease: Is a new treatment paradigm coming? Northern Health IDC brown bag lunch series.
7. May 12-13, 2017. Conference planning committee member: BC Rural Health Conference. Prince George, BC.
8. May 11, 2017. Conference Chair: Northern Reflections Medical Education Day. Prince George, BC.
9. Mar 22 & April 4, 2017. Workshop Facilitator: OSCE examiner training in the Northern Medical Program. Prince George, BC.
10. Nov 7, 2016. Workshop Facilitator: Northern Health IDC Research Days Conference. *Preparing for an Academic Career*. Prince George, BC.
11. June 10, 2016. Presenter: Rural Emergency Continuum of Care Conference. *Radiation Oncology Emergencies*. Prince George, BC.
12. June 8, 2016. Organizer and presenter: Northern Reflections Medical Education Day. Prince George, BC.
13. Mar 3, 2016. Facilitator of Module D: Fred Bryan's Master Teacher Program. Prince George, BC.
14. Feb 7, 2016. Invited Presentation: Radiation Oncology Case Studies; How to use questioning to teach diagnostic reasoning. Jasper, AB.
15. Jan 14, 2016. Facilitator of Module C: Fred Bryan's Master Teacher Program. Prince George, BC.
16. Jan 5, 2016. Invited Presentation: New changes in the curriculum of the NMP. Prince George, BC.
17. Nov 19, 2015. Facilitator of Module B: Fred Bryan's Master Teacher Program. Prince George, BC.
18. Oct 16, 2015. Invited Presentation *How the NMP can help me audit my practice and supervise students*. Prince George, BC.
19. Sep 17, 2015. Facilitator of Module A: Fred Bryan's Master Teacher Program. Prince George, BC.
20. Sep 15 & 17, 2015. Introduction to workplace based assessments (WBA) for the new MD Undergraduate Curriculum in UBC. Vancouver, BC.
21. May 27, 2015. Invited speaker at UBC Department of Surgery Grand Rounds. *Collecting Patient-Reported Outcomes on a Provincial Level*. Vancouver, BC.
22. Mar 26, 2015. Invited presenter to the multidisciplinary Haida Gwaii Medical Education Rounds. *Oncologic Emergencies*. Queen Charlotte City, BC.
23. Sep 26-28, 2014. Conference organizer and presenter at Northern Medical Education Conference. Jasper, AB.
24. June 5, 2014. Invited speaker to the Rural Rounds Videoconference Series. *Ask a Radiation Oncologist*. Video-linked to over 30 rural sites in BC.
25. June 3, 2014. Invited speaker at the Medical Oncology Grand Rounds. *Oligometastatic disease and the emerging role of stereotactic ablative radiotherapy*. Vancouver, BC.
26. May 22, 2014. Invited speaker at the 10<sup>th</sup> Anniversary Med Ed Days (UBC). *Challenges and opportunities for faculty development across the distributed medical program*. Vancouver, BC.
27. May 3, 2014. Invited speaker at the 2nd Realities of Northern Oncology Conference. *Palliative Radiation: Indications, Advances, and Education*. Prince George, BC.

28. Feb 14, 2014. Invited speaker at the Smithers Medicine Conference. *Teaching – Curriculum Renewal & Faculty Development*. Smithers, BC.
29. April 5, 2013. Invited speaker at Critical Care in the North, Rural to Referral. *Radiation Oncology Emergencies*. Prince George, BC, Canada.
30. Oct 11, 2012. Invited speaker to the University Hospital of Northern British Columbia's Nursing Workshop. *Introduction to Radiation Oncology and Oncologic Emergencies*. Prince George, BC, Canada.
31. May 16, 2012. Invited speaker to a Vanderhoof Family Practice CME event. *Radiotherapy basics and indications*.
32. May 5, 2012. Invited speaker at the 1<sup>st</sup> Realities of Northern Oncology Conference. *Radiation Oncology Primer*. Prince George, BC, Canada. 115 attendees - 67 evaluations of lectures
33. October 30, 2007. Invited speaker at the Burnaby General Hospital Palliative Care Interdisciplinary Rounds. *Hepatic Encephalopathy in Palliative Care*. Burnaby, BC, Canada.

## 2. CME activities as an attendee

1. Feb 5-8, 2016. Jasper Family Weekend CME retreat. Jasper, AB.
2. Nov 10, 2015. Direct Observation and Feedback workshop. Prince George, BC.

### (f) Visiting Lecturer

1. Invited speaker at the Alberta Medical Association, Section of Radiation Oncology Symposium. A Provincial Strategy to Balance Clinical Workload and Academics at Tertiary and Community Centres & Oligometastases: Current and Future Trials. Oct 8 and 9, respectively. Jasper, AB.
2. Invited Visiting speaker at Ottawa Cancer Program. Exploring, understanding, and changing prescribing practices in Radiation Oncology. Nov 20, 2019.
3. Invited speaker at the 1st cancerPRO meeting. Challenges and Successes of Implementing a Patient Reported Outcome Program across BC's Radiotherapy Program. Calgary, AB. Mar 4, 2017.
4. Invited speaker at Cancer Care Manitoba. *Effective Practice Change Strategies in British Columbia* as part of the Canadian Partnership Against Cancer's Radiotherapy Demonstration Project. Saskatoon, SK. Feb 28, 2017.
5. Invited speaker at Cancer Care Manitoba. *Effective Practice Change Strategies in British Columbia* as part of the Canadian Partnership Against Cancer's Radiotherapy Demonstration Project. Winnipeg, Manitoba. Feb 27, 2017.
6. Invited speaker at Tom Baker Cancer Centre Oncology Grand Rounds. *Collection and Utilization of Patient Reported Outcomes for care, quality improvement, and Research*. Calgary, AB. July 20, 2016.
7. Invited Keynote speaker at the 14<sup>th</sup> Annual Dalhousie Oncology Research Day. *Feasibility and Utility of Collecting Patient Reported Outcomes to guide Clinical Care, Quality Improvement, and Research*. Halifax, NS. May 19, 2016.
8. Invited speaker at Multidisciplinary Oncology Rounds. *Patient Reported Outcomes in Radiation Oncology*. Saint John, NB. May 17, 2016
9. Invited speaker at Radiation Oncology Grand Rounds. *Patient Reported Outcomes in Radiation Oncology*. Charlottetown, PEI. May 16, 2016.
10. Invited lecture at the University of Northern British Columbia. *Radiation Oncology and Radiobiology*. Nov 16, 2011.
11. Invited lecture at the University of Northern British Columbia. *Evaluation of Selection Bias in Clinical Trials*. Nov 17, 2010.

### (g) Educational Leadership

1. In July 2021 I was chosen as the first Associate Head, Research, Department of Surgery at UBC, which includes mentorship of faculty supervising trainees in research.
2. In March 2021 I was chosen as the Region 1 representative (BC and Alberta) for Radiation Oncology at the Royal College of Physicians and Surgeons of Canada.
3. Since 2017, I have been the Division Head of Radiation Oncology and Developmental Radiotherapeutics, where I am ultimately responsible for the BC Radiation Oncology Residency Program and Undergraduate Program. In this role I have advocated for changes to the undergraduate elective system to improve access to high quality residents, I oversee the awards structure, I mentor

all residents in their research endeavors, and guide the Program Directors in their decision making process. I also mentor each of the radiation oncologists at all 6 BC Cancer centres in their academic career and promotion, including opportunities for educational participation and leadership.

4. From 2013-2017 I was the Regional Director of Faculty Development for Northern BC facilitating many workshops, mentoring educational leaders, problem solving difficulties student's and teacher's encounters.

*(h) Curriculum Development & Innovation*

1. Northern Medical Program Curriculum Transition Team. 2013 - Present

*(i) Other Teaching & Learning Activities*

1. UBC, Northern Medical Program, CaRMS Practice Session, Feb 10, 2022
2. UBC, Northern Medical Program, CaRMS Practice Session, Feb 9, 2021
3. UBC, Northern Medical Program, CaRMS Practice Session, Jan 8, 2019
4. UBC, Northern Medical Program, CaRMS Practice Session, Jan 2, 2018
5. UBC, Northern Medical Program, CaRMS Practice Session, Jan 4, 2017
6. UBC, Northern Medical Program, CaRMS Practice Session, Jan 6, 2016
7. UBC, Northern Medical Program, CaRMS Practice Session, Jan 6, 2015
8. UBC, Northern Medical Program, Oral Examiner for Surgery Clerkship Exams. 2012 – Present
9. UBC, Radiation Oncology Residency Program, Oral Examiner for Senior Radiation Oncology Residents Annual Exam. 2010 – 2013

## 9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

### (a) *Areas of special interest and accomplishments*

My initial research focus was on health services delivery, with a focus on disparities in cancer care for rural and indigenous groups through my roles in the Northern Medical Program. I continue to pursue research in this area, and enjoy mentoring trainees in this area. After that, my health services delivery portfolio focused more specifically on prescribing practices of radiotherapy. My research demonstrating wide variability in single fraction radiotherapy prescription for bone metastases in BC (Olson *et al.* IJROBP 2014) has garnered international attention through the American Society of Radiation Oncology, and has been followed by several research projects where I subsequently designed a multipronged intervention (Olson *et al.* IJROBP 2016) to increase single fraction radiotherapy prescription, which has led to a meaningful and lasting change in practice in BC (Olson *et al.* IJROBP 2018) and has been the topic of multiple international press releases from the American Society of Radiation Oncology..

I am the Principal Investigator and Clinical Lead of the BC Cancer provincial program titled the Prospective Outcomes and Support Initiative (POSI) which is focused on collecting patient reported outcomes (PROs) on all patients receiving radiotherapy within BC while using the PRO to guide efficient and effective multidisciplinary care. Through this project, we have accrued nearly 1,000,000 patients in its first 8 years, demonstrating that population-based collection of PRO can be used for clinical care, quality improvement, and research. As a result, I have been selected by the Canadian Partnership of Quality Radiotherapy to lead Canada-wide expansion of PRO collection and use within the radiotherapy community, and I am an external expert on Cancer Care Ontario's PRO program. I received Michael Smith Foundation for Health Science Research funding to see PRO expansion and standardization across Canada, with a goal to compare efficacy and side effects of varying radiotherapy techniques on a population scale. As a testament to my internationally recognized expertise in PRO and quality of life, I have recently been invited to collaborate on the European Organization for Research and Treatment of Cancer (EORTC) update on the bone metastases (BM)-22 questionnaire update, and the creation of a new spinal cord compression subscale questionnaire creation.

My most prominent research to date is focused on stereotactic ablative radiotherapy (SABR) for oligometastases (variably defined as up to 3-5 metastases). I am the principal investigator on a population-based phase II trial of SABR in BC, titled SABR-5 which is investigating toxicity associated with SABR on a provincial population-based scale (SABR was only available on trial in this setting), which successfully accrued all 399 patients well within its target accrual phase, and was presented in the Clinical Trial and Innovation Session at ASTRO as one of 2 selected for a discussion, and highlighted in multiple press releases, and published in JAMA Oncology. In collaboration with centres across Canada, Australia, Scotland, and Netherlands, I was also the 2<sup>nd</sup> author on the open-label randomized phase II trial, titled SABR-COMET, which was published in The Lancet in 2019, which has changed practice internationally. As evidence of my international contribution in this area, I am the principal investigator on the follow-up international randomized phase III trial titled SABR-COMET-3 currently open to accrual internationally, and co-Principal Investigator on the sister trial SABR-COMET-10. Accrual for both of these studies are well underway despite opening just prior to the COVID-19 pandemic and is highly anticipated internationally. Most recently I received Canadian Cancer Clinical Trials Funding for the inaugural "Canadian Remote Access Framework for Clinical Trials" call for funding to supplement the expansion of COMET-3 accrual and trial activities in rural and First Nations communities in BC. I have multiple additional clinical trials in the development and application for funding phases, and plan to continue to build my expertise in clinical trial leadership and mentorship.

(b) Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)). **BOLD = current funding**

Granting Agency	Title	COMP Or Non-COMP	\$ Total (i.e. not annual amount)	Years	PI(s)	Co-I(s)	Role description (if not PI)
<b>PROSPECTIVE DATABASE COLLECTION OF OUTCOMES</b>							
Michael Smith Foundation for Health Research	Canada-Wide Comparison of Patient Reported Outcomes by Complexity of Radiotherapy Technique for Bone Metastases	C	445,000	2018 – 2022	Robert Olson	NA (Health Professional Investigator Award)	
PHSA-NH-UNBC Seed Grant	Feasibility of Sharing Patient Reported Outcomes between Oncology and Primary Care	C	10,000	2015-2016	Robert Olson	Bill Clifford, Vincent LaPointe	
BCCA: Varian Medical Systems Master Research Agreement	Collection of Outcomes for Provincial SABR Program	C	46,200	2014 - 2019	Alanah Bergman, Eric Berthelet	Parminder Basran, Hannah Carolan, Rezwan Chodhury, Fred Hsu, Derek Hyde, Mitchell Liu, Robert Olson, Devin Schellenberg, Steven Thomas, Rosie Vellani, Elaine Wai	Leading the patient reported outcome collection
BCCA: Varian Medical Systems Master Research Agreement	Prospective Outcomes and Support Initiative	C	1.14 million	2013 – 2018	Robert Olson, Wayne Beckham	Helena Daudt, Joanne Stephen, Ivo Olivotto, Scott Tyldesley, Gaurav Bahl, Tom Pickles, Gerlad Gelowitz, Amanda Bolderston, John French, Stephanie Aldridge, Frankie Goddwin, Ross Halperin	PI
<b>CLINICAL TRIALS</b>							

Varian Medical Systems	SIMPLIFY-SABR-COMET-PRO Randomized Phase III Trial	C	\$689,000	2022 - 2026	Robert Olson	David Palma, Devin Schellenberg, Alexander Louie	PI
Canadian Cancer Society: Challenge Grants	A multi-biomarker approach for defining the oligo-metastatic state using liquid biopsies (grant #707452)	C	\$450,000	2021 - 2024	Allison Allan	David Palma, Robert Olson	Co-I
Canadian Cancer Clinical Trials Network	Canadian Remote Access Framework for Clinical Trials (CRAFT): Proof of Concept Implementation Project (for SABR-COMET-3)	C	\$45,000	2021	Robert Olson	Shelby Bichel, Agnes Sauter, Benjamin Mou	PI
CIHR Project Grant	A phase III randomized controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) for Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer: SABR-COMET-3	C	\$699,380	2020 - 2026	Robert Olson	Alison Allan, David Palma, Stuart Peacock, Scott Tyldesley	PI
BC Cancer: Varian Medical Systems Master Research Agreement	RAPPLE 8 Gy / 1 fraction VMAT radiotherapy for brain metastases	C	\$250,000	2020 - 2022	Alan Nichol	Hannah Carolan, Nafisha Lalani, Roy Ma, Shilo Lefresene, Fred Hsu, Robert Olson, Benjamin Mou, Isabelle Vallieres, Andra Krauze	Co-I
BC Cancer: Varian Medical Systems Master Research Agreement	SUPR-3D: A Randomized Phase III Trial Comparing Simple Unplanned Palliative Radiotherapy versus 3D Conformal Radiotherapy for Patients with Bone Metastases	C	\$155,000	2019 - 2021	Robert Olson	Nick Chng, Quinn Matthews	PI

CIHR Planning and Dissemination Grant	Future of Stereotactic Ablative Radiotherapy (SABR) Trials in Oligometastatic Cancer: Continuing Canadian-Led International Investigations in Radiation Therapy	C	\$9,980	2022 - 2023	Robert Olson	Devin Schellenberg, David Palma	PI
Varian Medical Systems	Phase III randomized trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: SABR-COMET-3	C	\$500,000	2019 - 2024	Robert Olson	David Palma, Devin Schellenberg, Alexander Louie	PI
Canadian Cancer Society: Innovation to Impact	Reducing toxicity in whole breast adjuvant radiotherapy using a novel breast positioning device	C	\$345,525	2018 - 2022	Cheryl Duzenli, Robert Olson	Theodora Koulis, Maha Almahmudi, Christina Aquino-Parsons, Alanah Bergman, Tanya Berrang, Elisa Chang, Joel Singer, David Voduc, Isabel Serrano	Co-PI
CIHR	CCTG HN.10	C	\$960,628	2018 - 2024	Wendy Parulekar, Scott Bratman	Eric Berthelete, Isabelle Gauthier, Alex Hammond, Nader Khaouam, Shazia Mahmood, Robert Olson, Kevin Ramchandrar, Ken Schneider, George Shenouda, Khalil Sultanem, James Wright	Collaborator, UBC Lead
BCCA: Varian Medical Systems Master Research Agreement	Phase II non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases	C	165,000	2017 - 2023	Robert Olson		PI
<b>EDUCATION INNOVATION</b>							

UBC Teaching and Learning Enhancement Fund	Developing an education module of integrative breast pathology for UBC medical students		38,000	2015 - 2016	Diana Ionescu	Malcolm Hayes, Greg Naus, Kuo Kuo-Hsing, Robert Olson, Christine Wilson	Oncologist and Educator perspective
UBC Teaching and Learning Enhancement Fund	Case-Based Learning Tutor Training Program	C	45,000	2014 - 2015	Sandra Jarvis-Selinger	Gisele Bourgeois-Law, Barry Mason, Roxanna Smallwood, Robert Olson, Andrea Gingerich, Linlea Armstrong, Mike Purdon, Jane Gair, Dawn DeWitt, Ashley Smith	Northern BC's perspective
<b>HEALTH SERVICES RESEARCH</b>							
Canadian Cancer Society – Accelerator Grant	Operationalizing a Panel of Quality Measures for the Evaluation of Virtual Care in Oncology Practice	C	98,398	2022 - 2024	Monika Krzyzanowska	Lisa Barbera, Alejandro Berlin, Matthew Cheung, Aisha Lofters, Helen McTaggart-Cowan, Simron Singh, Robert Olson, Ambreen Sayani	Co-Applicant
Michael Smith Health Research BC Convening and Collaborating award	Developing a collaborative research agenda to improve the care of patients living with metastatic breast cancer in British Columbia	C	14,950	2022 - 2023	Helen McTaggart-Cowan & Stephen Chia	S Beck, AF Howard, S Izadi-Najafabadi, J Kaur, L Lambert, N LeVasseur, F Mitchell, R Olson	Co-Investigator
Oncology Nursing Society	Designing a Tailored Self-Management App to Support Older Adults with Cancer and Multimorbidity	C	50,000 USD	2021 - 2023	Kristen Haase	Mariano, Currie, Tompson, Puts, Hung, Howell, Olson, McGrenere	Collaborator
PHSA-NH-UNBC Seed Grant	Improving Mental Health Service Users' Experiences of Cancer Care via Patient Engagement	C	10,000	2018 - 2019	Roseann Larston	Robert Olson, Sarah deLeuw, Nansi Long, Lynn Smolaik, Michelle Waller	PHSA-NH-UNBC Seed Grant
PHSA-NH-UNBC Seed Grant	Mental Health Service Users' and Carers' Experiences of Cancer Care	C	10,000	2017 - 2018	Candida Graham & Robert Olson	Russell Callaghan, Sarah deLeuw	PHSA-NH-UNBC Seed Grant



British Columbia Medical Association: Shared Care Committee	Transitions in Care: Cancer Survivorship in Primary Care	C	420,000	2014 - 2016	Karen Blain	Robert Olson, Phil White, Isabelle Linden	Physician co-Lead
Canadian Breast Cancer Foundation	Investigating bottlenecks and barriers to breast cancer care in Haida Gwaii	C	49,982	2013 - 2015	Robert Olson	Tracy Morton, Pamela Tobin, Candice Manahan, Caitlin Blewett, Bill Clifford	PI
Vancouver Foundation	Investigating bottlenecks and barriers to cancer care in Haida Gwaii	C	57,002	2013 - 2014	Robert Olson	Tracy Morton, Pamela Tobin, Candice Manahan, Caitlin Blewett, Bill Clifford	PI
Applied Research in Cancer Control	Assessing utility and motivation practice change in palliative radiation therapy	C	68,000	2012 - 2014	Robert Olson	Ivo Olivotto, Joanne Stephen, John French, Helena Daudt	PI
Underwear Affair (BC Cancer Foundation)	Impact of community size on staging, treatment, and outcomes in rectal cancer	C	16,250	2012 - 2013	Shilo Lefresne & Robert Olson	Winson Cheung, Ryan Woods, Caroline Speers	PI
Northern Cancer Control Strategy	Impact of community size on patterns of practice in rectal cancer	C	2,000	2012	Robert Olson & Shilo Lefresne	Winson Cheung, Ryan Woods, Caroline Speers	PI
Canadian Breast Cancer Foundation	Breast Cancer in British Columbia's Northern Communities: the Cancer Care Spectrum	C	142,800	2011 - 2012	Nadine Caron	Arminee Kazanjian, Chris Bajdik, Robert Olson, Scott Tyldesley	Epidemiology and radiation oncology expertise
CARO-Elekta Fellowship	Optimization of High Precision Radiotherapy Utilization and Resource Allocation using Operations Research Methodologies	C	75,000	2011 - 2012	Jeff Cao	Robert Olson, Scott Tyldesley	Supervisor
Public Health Agency of Canada	Delivering Cancer Survivorship Care to Rural and Remote Communities	C	213,054	2010 - 2012	Robert Olson	Amanda Ward, Pam Tobin, Arminee Kazanjian, Nadine Caron, Christopher Longo, Fuchsia Howard	PI
ASRT Education and Research Foundation	Assessment of Rural and Urban Family Physicians Knowledge of Palliative Radiation Therapy	C	9,971	2010	Jenny Soo	John French, Colleen Mcgahan, Scott Tyldesley, Robert Olson, & Sonca Lengoc	Lead the analysis and manuscript preparation

<b>DISCOVERY GRANTS</b>							
Northern Cancer Control Strategy	Unlocking the Potential of Shared Care: Cancer Survivorship	C	2,000	2012	Dan Horvat	Richard Doll, Arminee Kazanjian, Robert Olson, Amanda Ward, Phil White	Lead on the cancer component
<b>PLANNING GRANTS</b>							
CIHR	Survivorship: Shared care between Family Physicians and specialists	C	21,101	2011 – 2012	Dan Horvat	Richard Doll, Arminee Kazanjian, Robert Olson, Geoff Payne, Jeff Sisler, Amanda Ward, Phil White	Lead on the cancer component
<b>OPERATING</b>							
Northern Medical Program Seed Grant	Prognostic Utility of Distress Screening in Lung Cancer	C	10,000	2011	Robert Olson, Wolfgang Linden	N/A	PI
Shared Care Committee	Northern Partners in Shared Care	C	345,000	2012	Dan Horvat	Paul Winwood, Robert Olson, Bill Clifford, Hadi Haidar, Ray Markham, Ronald Chapman, Denise McLeod	Lead on the cancer component
Shared Care Committee	Northern Partners in Shared Care	C	870,000	2014 – 2016	Dan Horvat, Paul Winwood	Robert Olson, Bill Clifford, Hadi Haidar, Ray Markham, Ronald Chapman, Denise McLeod	Lead on the cancer component
<b>BASIC SCIENCE</b>							
PHSA-NH-UNBC Seed Grant	Versican in Mammary Epithelial Cell Invasion	C	10,000	2017-2018	Sean Maurice, Connie Eaves, Heather Wozney	Robert Olson, Michelle Suter	PHSA-NH-UNBC Seed Grant
Northern Medical Program Seed Grant	Cytoplasmic Expression of APE-1 in human cancer cells	C	14,000	2011 - 2012	Chow Lee, Robert Olson	N/A	PI
<b>SURVEY RESEARCH</b>							

CIHR Team for Supportive Care in Cancer	Exploring medical and psychosocial needs of cancer survivors	C	20,470	2010	Fuchsia Howard	Richard Doll, Kirsten Smilie, Karen Goddard, Sheila Pritchard, Robert Olson	Provided expertise from my MSc thesis
<b>DIAGNOSTIC TEST ASSESSMENT</b>							
Porte Neuro-Oncology Endowment Fund	Evaluation of two cognitive screening tools for use in neuro-oncology	C	8,474	2008	Robert Olson & Michael McKenzie	Maureen Parkinson, Grant Iverson, Brian Brooks, Hannah Carolan	PI
Fraser Valley Interdisciplinary Research Grant	Validation of the Montreal Cognitive Assessment in brain tumour patients	C	9,625	2008	Robert Olson & Maureen Parkinson	Michael McKenzie, Grant Iverson, Hannah Carolan, Gina Mackenzie	PI

(c) Research or equivalent contracts, including funding for clinical trials (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)). **BOLD = current funding.**

Granting Agency	Title	COMP	\$	Year	Principal Investigator	Co-Investigator(s)
Canadian Partnership Against Cancer	Improving Palliative and End-of-Life Care and Quality of Life through Comprehensive Application of Patient Reported Outcomes (PROs) and Early Integration of Palliative Care (Contract: partnership agreement between the Canadian Partnership for Quality Radiotherapy and the Canadian Partnership Against Cancer)	NC	1,000,000	2018 – 2019	Michael McKenzie	Bernice Budz, Sara Camano, Pippa Hawley, Lee Ann Martin, Robert Olson, Rick Sawatzky, Tamara Shenkier, Frances Wong
Canadian Partnership Against Cancer	Developing a National Patient Reported Outcomes Collection Program (Contract: partnership agreement between the Canadian Partnership for Quality Radiotherapy and the Canadian Partnership Against Cancer)	NC	450,000	2017 - 2019	Erika Brown, Michael Milosevic	Lisa Barbera, Louise Bird, Michael Brundage, Amanda Caissie, Carol-Anne Davis, John Kildea; Eshwar Kumar, Brian Liszewski, Ross MacDonald, Robert Olson, Anubha Prashad, Tom Purdie, Lianne Wilson

Northern Medical Program (UBC/UNBC)	Research Faculty (renewal)	C	100,000 (per year)	2017 – current	Robert Olson	N/A
Northern Medical Program (UBC/UNBC)	Research Faculty (renewal)	C	95,000 (per year)	2013 – 2016	Robert Olson	N/A
BCCA: Varian Medical Systems Master Research Agreement	Phase II trial of hippocampal sparing whole brain radiotherapy	C	60,000 (total)	2013 – 2014	Devin Schellenberg	Eric Berthelet, Robert Olson, Hannah Carolan
Canadian Breast Cancer Foundation	Omission of radiotherapy for women with low risk, luminal A breast cancer	C	185,230 (total)	2012 – 2017	Sally Smith	David Voduc, Robert Olson, Arthur Cheung, Winkle Kwan, Melanie Reid, Torsten Nielson
BCCA: Varian Medical Systems Master Research Agreement	Novel SBRT technique (VASER) for endobronchial tumours	C	25,170 (total)	2012 - 2013	Dawn Owen & Mitchell Liu	Hannah Carolan, Robert Olson, Annette McWilliams, Stephen Lam, Tawaimas Shaipanich, Rustom Dubash, William Kwa
Northern Medical Program (UBC/UNBC)	Research Faculty	C	85,000 (per year)	2010 – 2013	Robert Olson	N/A

(d) *Invited Presentations*

1. Feb 3, 2023. Invited speaker at Scottish Oligometastatic SABR Network Educational Event. International trials in SABR for Oligometastatic Cancer.
2. Aug 2, 2022. Invited speaker at Tom Baker Cancer Centre Grand Rounds. Past, Present, and Future of SABR trials for Oligometastatic Cancer.
3. July 4, 2022. Invited speaker at the UK Imaging and Oncology (UKIO) Congress. Considerations for implementing an international clinical trial - lessons learned from SABR-COMET-3.
4. June 21, 2022. Invited speaker at the Canadian Partnership Against Cancer Board of Directors Reception. Canadian Remote Access Framework for Clinical Trials.
5. June 17, 2022. Invited speaker at Canadian SABR conference. SABR Oligometastases: Future. Kelowna, BC.
6. Jun 9, 2022. Invited speaker at Varian MSL Lecture Series. Past, Present, and Future Clinical Trials of SABR for Oligometastatic Disease. Virtual.
7. May 26, 2022. Invited speaker at BC Cancer – Victoria Radiation Oncology Rounds. COMET-3 and Future SABR trials in development.
8. Mar 8, 2022. Invited speaker at Cancer Trials Ireland Grand Rounds. SABR-COMET Trials: Past, Present, and Future.
9. Feb 17, 2022. Invited speaker at the Life Sciences British Columbia Annual Conference: Access to Innovation 2022. Virtual meeting. Decentralized Clinical Trials: the Way of the Future.
10. Dec 14, 2021. Invited speaker at the Life Sciences British Columbia, Showcase Series: Prince George. Leading paradigm changing international clinical trials from Northern BC.
11. Nov 30, 2021. Invited speaker: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3

- metastases) cancer: SABR-COMET-3 Site Activation. Beatson West of Scotland Cancer Centre. Glasgow, Scotland.
12. Nov 19, 2021. Invited presentation at BC Cancer Summit. SABR clinical trials in BC: where are we and where do we go next?
  13. Nov 1, 2021. Invited speaker at the WB & MH Chung Lectureship and Research Day, Department of Surgery, University of British Columbia. *Population-based phase II trial of SABR in the setting of 1-5 oligometastatic lesions: Preliminary Results from SABR-5*. Vancouver, BC, Canada.
  14. Sep 23, 2021. Invited trial (one of three) highlighted in the impACCT Trial Rounds session of the 3CTN Annual Meeting.
  15. Jun 29, 2021: Invited Presentation: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 metastases) cancer: SABR-COMET-3 site activation. St. Luke's Radiation Oncology Network and Bon Secours Radiotherapy Cork in partnership with UPMC Hillman Cancer Centre. Ireland.
  16. May 28, 2021. Invited speaker: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 metastases) cancer: SABR-COMET-3 site activation. The Alfred Hospital. Melbourne, Australia.
  17. May 14, 2021. Invited speaker: Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 metastases) cancer: SABR-COMET-3 site activation. Edinburgh Cancer Centre. Edinburgh, UK.
  18. Feb 3, 2021. Invited Presenter at the Canadian Organization of Medical Physics (COMP) Winter School. Patient Reported Outcomes from a Patient's Perspective.
  19. Oct 26, 2020. Invited Presenter at BC Cancer – Kelowna Grand Rounds. Stereotactic Ablative Radiotherapy for Oligometastases: Past, Present, and Future.
  20. November 24, 2018. Invited Plenary Presentation at the BC Cancer Summit. Stereotactic Ablative Radiotherapy Update.
  21. Feb 12-15, 2018. Invited Presenter at the COMP Winter School. Linking Patient Reported Outcomes to Radiation Plan Parameters & Patient Reported Outcomes: Can we standardize our Assessment? Lake Louise, AB. Linking Patient Reported Outcomes to Radiation Plan Parameters & Patient Reported Outcomes: Can we standardize our Assessment?
  22. Nov 25, 2016. Invited speaker to the BC Provincial Sarcoma Retreat. Potential Utility of Patient Reported Outcomes to Guide Clinical Care, Quality Improvement, and Research for Patients with Sarcoma. Vancouver, BC.
  23. Sep 13, 2016. Invited speaker to Canadian Partnership in Quality Radiotherapy (CPQR) Annual Meeting. *Expanding collection of patient reported outcomes from BC to the rest of Canada*.
  24. Oct 9, 2015. Invited speaker at the BCCA SBRT retreat. *Oligometastases Treatment & POSI*. Vancouver, BC.
  25. Sep 25, 2015. Invited speaker to the SAHCSI Research Conference. *The Prospective Outcomes and Support Initiative. Care and Research*. Kelowna, BC.
  26. Mar 24-26, 2015. Invited speaker for research knowledge translation. *Cancer Care in Haida Gwaii*. Haida Gwaii, BC.
  27. Feb 28, 2014. Invited speaker at the BCCA Stereotactic Ablative Radiotherapy Provincial Retreat. *Collecting patient reported outcomes for SABR using POSI*. Vancouver, BC.
  28. Feb 14, 2014. Invited speaker at the Smithers Medicine Conference. *Teaching – Faculty Development and Curriculum Renewal*. Smithers BC.
  29. Jan 21, 2014. Invited speaker at the Canadian Palliative Radiation Oncology Group. *BC's Provincial Prospective Outcomes and Support Initiative (POSI) piloted in bone metastases*. Canada wide electronic presentation.
  30. Aug 23, 2012. Invited speaker at the Provincial Health Services Authority board meeting. *Cancer Research Program in Northern BC*. Prince George, BC, Canada.
  31. Mar 5, 2012. Invited speaker at the provincial Head and Neck Cancer Rounds. *Updates from the Multidisciplinary HN Conference in Phoenix, AZ*. Vancouver, BC, Canada.
  32. Feb 17, 2012. Invited speaker at the provincial Head and Neck Cancer Retreat. *Retrospective comparison of 2 feeding tube approaches for H&N cancer patients*. Vancouver, BC, Canada.
  33. November 7, 2011. Invited speaker at the WB & MH Chung Lectureship and Research Day, Department of Surgery, University of British Columbia. *Effect of community population size on breast cancer screening, stage distribution, treatment utilization, and survival outcomes*. Vancouver, BC, Canada.
  34. November 1, 2011. Invited speaker at the Northern Health Research Days 2011. *Northern Cancer Control Strategy Research Panel*. Prince George, BC, Canada.

35. February 13, 2009. Invited speaker at the BC Cancer Agency Neuro-Oncology Symposium. *Collaborations between the BCCA and the BC Mental Health & Addiction Services*. Vancouver, BC, Canada.
36. September 22, 2011. Invited speaker at the 1<sup>st</sup> Northern Oncology Lecture. *Effect of community population size on breast cancer screening, stage distribution, treatment utilization, and survival outcomes*. Prince George, BC, Canada.
37. June 27, 2011. Invited speaker at the BCCA Provincial Stereotactic Body Radiotherapy Meeting. *Pros and cons of maintaining RTOG clinical trial membership*. Vancouver, BC, Canada.
38. May 27, 2011. Invited speaker at the BCCA Provincial Breast Cancer Meeting. *Impact of IMN radiation: BCOU analysis*. Vancouver, BC, Canada.
39. October 22, 2010. Invited speaker at the WB & MH Chung Lectureship and Research Day, Department of Surgery, University of British Columbia. *Potential Research Collaboration between UBC, BCCA and Northern Health within the department of surgery*. Vancouver, BC, Canada.
40. April 24, 2009. Invited speaker at the BC Cancer Agency Provincial Breast Radiation Oncology Retreat. *Impact of internal mammary node inclusion in the radiation treatment volume on the outcomes of breast cancer patients treated with locoregional radiation*. Vancouver, BC, Canada.

(e) *Invited Participation*

(f) *Conference Participation (Organizer, Chair, Moderator, etc.)*

1. Conference co-Organizer, Chung Research Day, UBC Department of Surgery, 2021
2. Workshop presenter, 2017, Canadian Association of Radiation Oncology Annual Conference. *Pan-Canadian PRO collection: Working Together to Advance Patient Care*
3. Workshop Moderator, 2016, Northern Health/UNBC IDC Research Days.
4. Advisory Committee, 2013 Canadian Rural Health Research Society Annual Conference.
5. Knowledge Mobilization Panel Member, Northern Health Research Days 2012.
6. Planning committee member and faculty, 1st Annual Realities of Northern Oncology Conference (RONOC) 2012.
7. Moderator, Pathways and Process poster session, Canadian Association of Radiation Oncology (CARO) Annual Conference 2011.
8. Conference abstract reviewer, Canadian Rural Health Research Society
  - a. 2013 (6)
9. Conference abstract reviewer, Canadian Association of Radiation Oncology Annual Meeting
  - a. 2017 (20)
  - b. 2016 (10)
  - c. 2015 (26)
  - d. 2014 (2)
  - e. 2013 (11)
  - f. 2012 (9)
  - g. 2011 (7)

(g) *Other Presentations*

1. Dec 9, 2021. Population-based phase II trial of SABR for up to 5 Oligometastases: Preliminary Results of the SABR-5 trial. Northern BC Research and Quality Conference 2021
2. Mar 4, 2019. Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic Disease: Is a New Treatment Paradigm Coming? UNBC Research Week 2019.
3. Dec 10, 2011. Invited keynote speaker at the 2011 Haida Gwaii Health Fair. Breast Cancer in British Columbia. Haida Gwaii, BC, Canada.
4. June 18, 2010. Invited speaker at the BC Cancer Agency Radiation Oncology Residents' Research Day. Prospective comparison of the prognostic utility of two cognitive screening tests in patients with brain metastases. Vancouver, BC, Canada.
5. June 19, 2009. Invited speaker at the BC Cancer Agency Radiation Oncology Residents' Research Day. Relationship between the surgical cavity and the cutaneous setup markers used in the Canadian randomized trial of accelerated partial breast irradiation. Vancouver, BC, Canada.

6. June 20, 2008. Invited speaker at the BC Cancer Agency Radiation Oncology Residents' Research Day. Sensitivity of the Mini Mental State Examination in brain tumour patients. Vancouver, BC, Canada.
7. June 15, 2007. Invited speaker at the BC Cancer Agency Radiation Oncology Residents' Research Day. Feasibility study of the Montreal Cognitive Assessment in patients with brain metastases. Vancouver, BC, Canada.

(h) *Other Scholarship of Education Activities*

As the Regional Director of Faculty Development of Northern BC, I developed collaborations across BC to improve delivery of education within the UBC medical program. As an example, I was a co-investigator on a funded project to improve Faculty Development for the new Case Based Learning (CBL) program of the medical program (previously Problem Based Learning), which is one component of the curriculum renewal plan. In addition, I developed a Master Teacher Program for Northern BC, predominantly housed in Prince George. Currently, as the Associate Head, Research, Department of Surgery, I am promoting further mentorship of surgical residents in all Divisions in their research activities, with a focus on pairing residents 1:1 with an appropriate mentor. There is a particular focus to promote surgical education research, which I do not perform as a researcher, but support in my administrative role.

(i) *Other Professional Contributions*

I developed the Vancouver Rapid Access Clinic (VARA), which is an interdisciplinary clinic with RNs, radiation therapists, an Advanced Practice Nurse, a Nurse Practitioner and several Radiation Oncologists at the BC Cancer Agency – Vancouver Centre., when I was a junior staff. This clinic triages new palliative lung cancer patients into a weekly clinic, where the interdisciplinary team approaches many complex issues that are faced by these patients. We have demonstrated an improvement in efficiency, and better patient outcomes with this clinic.

I am involved in several projects demonstrating that peer-review quality assurance of radiotherapy plans improves the quality of radiation, including publications in the *International Journal of Radiation Oncology, Biology, Physics* and the *Journal of Thoracic Oncology*. These projects have led to more widespread routine use of QA throughout the six BC Cancer Agency centres, as well as internationally.

I contribute internationally to the Radiation Oncology community by regularly reviewing for the top level radiation oncology journals including over 30 times for the *International Journal of Radiation Oncology, Biology, Physics*. Furthermore, I represent the radiation oncology community internationally as the radiation oncology section editor for the *Journal of Supportive Care in Cancer*, managing approximately 150 manuscripts to date.

## 10. **SERVICE TO THE UNIVERSITY**

(a) *Areas of special interest and accomplishments*

From 2013-2017, I was selected as the first Regional Director of Faculty Development for Northern BC. In this role I reported to the Regional Associate Dean, Northern BC and the Assistant Dean of Faculty Development for UBC. As of 2017, I am the provincial Division Head of Radiation Oncology and Developmental Radiotherapeutics, as the only division head leading from Prince George, BC. I am also the Research Lead for the Northern Medical Program (collaboration between UBC and UNBC), with a goal to increase the research culture in Northern Health, UNBC, and their partners. Most recently I was selected as the first Associate Head, Research, Department of Surgery at UBC, where I am leading the vision to grow the academic output of the Department.

(b) *Memberships on committees, including offices held and dates (ordered by Division, Department, FoM, and UBC)*

1. Department of Surgery, Division of Radiation Oncology and Developmental Radio-therapeutics
  - a. Member, Merit Review Committee, Jan 2022 - Present
  - b. Resident Research Coordinator, Radiation Oncology, 2016 – Jan 2019.
  - c. Member, Radiation Oncology Undergraduate Training Committee, 2012 – Present
  - d. Interviewer, Radiation Oncology Residency Program, 2012, 2017-2019
  - e. Member, BCCA, Peter Poon Memorial Award Committee, 2011 – 2013, 2015-2019
  - f. Member, Radiation Oncology Residency Training Committee, Aug 2010 – Nov 2013; July 2016 - Present
2. Department of Surgery
  - a. Associate Head, Research, 2021 - Present
  - b. Member, Executive Committee, 2017 - Present
  - c. Member, Appointment, Reappointment, Tenure and Promotion Committee, 2013 – 2016
    - i. May 2, 2013
    - ii. Jul 19, 2013
  - d. Member, Department of Surgery Award Adjudication Committee, 2011 – Present
3. Faculty of Medicine
  - a. Interviewer, Northern and Rural Panel Interview, Feb 12, 2023
  - b. Search Committee, UBC Division Head, Medical Oncology, 2020
  - c. Selection Committee, UBC Masters of Physical Therapy, Research Lead, 2020
  - d. UNBC Health Research Leadership Council, 2018 – Present (UBC Northern Medical Program representative)
  - e. Research Lead, Northern Medical Program, 2017 - Present
  - f. Member, Dean's Advisory Search Committee for Assistant Dean, Faculty Development, 2015
  - g. Lead, Faculty Development for Workplace Based Assessment, 2015
  - h. Review Committee, Assistant Dean, Faculty Development position, 2014
  - i. Member, Inter-professional Education Committee, Northern Medical Program, May 2014 - 2017
  - j. Member, Faculty Development for Large Group Learning Committee, Apr 2014 - 2016
  - k. Adjudicator, MD Undergraduate Student Research Scholarship review Committee, 2012, 2013, 2015, 2016, 2017, 2018
  - l. Member, Continuing Professional Development Committee, Dec 2013 – 2015
  - m. Member, Faculty Development Committee, Oct 2013 - 2017
  - n. Member, Curriculum Transition Team – Northern Medical Program, Oct 2013 – Present
  - o. Faculty, Northern Medical Program, Sep 2010 – Present
4. UBC
  - a. Adjudicator, Killam Graduate Teaching Assistant Award, 2012

(c) *Faculty mentoring*

**Mentorship of Early Career Faculty:** As the Division Head of Radiation Oncology for the province, including all six BC Cancer centres, I am constantly mentoring junior faculty in their teaching and research endeavours. As the Associate Head, Research, Department of Surgery, a particular focus of this leadership role is growing the mentorship of junior faculty in their clinical research program. I am responsible for matching junior: senior faculty, and am developing an award program for mentors.

(d) *Other service, including dates*

1. Faculty Examiner, Year 3 Surgery Oral Examinations, UBC Northern Medical Program
  - a. Apr 24, 2014
  - b. Apr 18, 2013
  - c. Dec 20, 2012
2. Education Lead, Radiation Oncology, UBC Northern Medical Program; 2012 – Present
3. Resident internal reviewer of UBC Residency Programs:
  - a. Adult Nephrology, Nov 27, 2009
  - b. Pediatric Gastroenterology, Oct 6, 2008



- c. Family Medicine (Victoria), Jun 13, 2006
- d. Pediatric Neurology, Feb 24, 2006
- e. Medical Genetics, Dec 9, 2005 (observer)
- 4. Faculty internal reviewer of UBC Residency Programs:
  - a. Gynecological Oncology, Jun 1, 2011

## 11. **SERVICE TO THE HEALTH PROFESSIONS/HEALTH AUTHORITIES**

### (a) *Areas of special interest and accomplishments*

I was the first physician hired to the BC Cancer Agency - Centre for the North, in Prince George, BC. I was actively recruited while in my residency program, and subsequently worked at the Vancouver Centre while construction was underway. As the first physician I was heavily involved in clinical start-up, equipment purchases, protocol development, and hiring of subsequent staff. I estimate that I volunteered several hundred hours from 2010 - 2012 in preparation for the opening of the new cancer centre in November 2012. I am the founding Medical Director of the BCCA's Prospective Outcomes and Support Initiative (POSI) which runs at all six BCCA centres, focused on innovating collection of patient reported outcomes, and using them to guide post treatment care and fuel future research. To date over 1,000,000 patient reported outcome questionnaires have been completed in POSI and hundreds of thousands of patients have been offered support in a multidisciplinary setting empowered by electronic capture and utilization of patient reported outcomes. I am involved in multiple leadership positions in PHSA and Northern Health, including the Research Lead and BC Cancer – Prince George, and a member of the Clinical Research Advisory Committee for Northern Health.

### (b) *Memberships on committees, including offices held and dates*

1. Vice Chair, Medical Advisory Committee, BC Cancer. March 2022 - Present
2. Member, Data Validation Working Group, PHSA. Jan 2022 - Present
3. UBC Representative, PHSA MAC Credentialing Committee. Jan 2022 - Present
4. Member, Clinical Research Advisory Committee, Northern Health. Jun 2020 - Present
5. Selection Committee, Director Research, Evaluation & Analytics, Northern Health. Nov/Dec 2019
6. Member, BCCA Radiation Oncology Department Head Committee, 2016 - 2022
7. Member, PRISM Working Group, BCCA. Nov 2015 - Present
8. Member, Secondary Data Access Committee, BCCA. Mar 2015 - 2019
9. Member, Clinical Trials Provincial Steering Group, BCCA. Nov 2014 - Present
10. Advisor, Medical Advisory Committee, BCCA (provincial). Nov 2014 – 2017
11. Member, Standard Operating Procedure Committee, BCCA Provincial Research, Jan 2014 – Present
12. Member, Northern Health Research Review Committee, Dec 2013 - Feb 2015
13. Medical Director, Prospective Outcomes and Support Initiative, BCCA. 2013 - 2020
14. Member, BCCA, Anita Cochrane Memorial Endowment Fund Committee, Nov 2013 – 2015
15. Chair, Research Committee, BC Cancer - Centre for the North, May 2013 - Present
16. Member, BCCA Provincial Clinical Design Team: iPad Mobility project. 2012 - 2013
17. Member, BCCA Provincial Survivorship Steering Committee, 2011 – 2015
18. Chair, BCCA Grace Shane Bursary Selection Committee 2011, 2012, 2013, and 2016
19. Member, BCCA, SBRT group, 2010 – Present
20. Director, BCCA CN Radiation Oncology Fellowship Program, 2011 – Present
21. Member, Medical Equipment Evaluation Team – BCCA Centre for the North Equipment Procurement process, 2011 – 2012
22. Founder & Member, Vancouver Palliative Rapid Access Group, 2011 – 2013
23. Member, BCCA working group to avoid inadvertent radiation to pregnant patients, 2010 – 2012
24. Member, BCCA Breast Tumor Group, 2010 – Present
25. Member, BCCA Head & Neck Tumor Group, 2010 – Present
26. Member, BCCA Lung Tumor Group, 2010 – Present

### (c) *Other service, including dates*

## 12. SERVICE TO THE COMMUNITY

### (a) *Areas of special interest and accomplishments*

I am regularly asked to review grants for international research organizations and currently I am the only member from BC Cancer on the Advisory Council for Clinical Trials BC. I am the Radiation Oncology Associate Editor for journal Supportive Care in Cancer, an international leading journal in its area. I have led national expansion of patient reported outcome standardization within Radiation Oncology through my work with Canadian Partnership for Quality Radiotherapy since 2016, which has led to my invitation to multiple provinces to help initiate their programs, as well as the recent invitation as the guest editor for a special issue on *Patient Reported Outcome Use in Radiation Oncology Research and Routine Clinical Care* in Current Oncology ([https://www.mdpi.com/journal/curroncol/special\\_issues/Patient-Reported\\_Outcome\\_Use\\_in\\_Radiation\\_Oncology\\_Research](https://www.mdpi.com/journal/curroncol/special_issues/Patient-Reported_Outcome_Use_in_Radiation_Oncology_Research)), in recognition of my international leadership both clinically and academically in patient reported outcome use and research. I acted as an international expert speaker and panelist for the U.S. Food and Drug Administration for a public forum on the use of ablative techniques for metastatic cancer, on April 5 & 6, 2022, a testament to my international reputation.

### (b) *Memberships on scholarly societies, including offices held and dates*

1. Region 1 representative (BC and Alberta) Specialty Committee for Radiation Oncology, Royal College of Physicians and Surgeons of Canada, 2021 – Present.
2. Study Steering Committee, OligoRare Clinical Trial (European Organization for Research and Treatment of Cancer), 2020 – Present
3. Advisory Council, Clinical Trials BC; British Columbia Academic Health Science Network. 2019 - Present
4. Member, National PRO conference planning committee, 2018, 2019
5. Invited Member, Society of Palliative Radiation Oncology (International Society of 85 invited members from 17 countries). Nov 2014 - Present
6. Member, Clinical Grant Review Panel, Canadian Breast Cancer Foundation: BC/Yukon Division, Jan 2014 & Jan 2015 (invited)
7. Member, Academic Research Committee of the Screening Mammography Program of BC, 2012 - 2013
8. Member, Royal College of Physicians and Surgeons of BC, 2010 – Present
9. Member, American Society for Therapeutic Radiation and Oncology (ASTRO), 2010 – Present
10. Associate Member, American Society for Clinical Oncology (ASCO), 2009 – Present
11. Member, Canadian Association for Radiation Oncology (CARO), 2005 – Present
12. Member, BC Medical Association, 2005 – Present
13. Member, Alberta Medical Association, 2002 – Present

### (c) *Memberships on other societies, including offices held and dates*

1. Patient Reported Advisory Committee – Cancer Care Ontario – Invited External Expert
  - a. Steering Committee Invited expert – March 2019 - Present
2. Canadian Partnership for Quality Radiotherapy
  - a. Steering Committee Member, Oct 2016 – present
3. British Columbia Association of Radiation Oncologists
  - a. Executive Committee, Jan 2013 – Present
  - b. Member, Sep 2010 – Present
4. Canadian Association of Radiation Oncology
  - a. Communication Committee, Jan 2021 - Present
  - b. Symptom Control in Radiation Oncology Advisory Group, Sep 2010 – Present
  - c. Canadian Partnership for Quality Radiotherapy, Sep 2010 – Present
5. St. John Ambulance
  - a. British Columbia Branch Executive Committee Member, 2009 – 2010
  - b. Alberta Public Relations Officer, 2003 – 2005
  - c. Calgary, Division 136 Community Service Coordinator, 1999 – 2003
  - d. Calgary Brigade Member, 1998 – 1999

6. Canadian Association of Interns and Residents
  - a. Education and Professionalism Committee Member. 2008 – 2009
  - b. External Residency Program Reviewer: Neuro-radiology (Ottawa), June 3, 2008.

(d) *Memberships on scholarly committees, including offices held and dates*

(e) *Memberships on other committees, including offices held and dates*

1. Northern BC Shared Care Committee member, May 2011 – 2015

(f) *Editorships (list journal and dates)*

1. Guest Editor (2021): Current Oncology special issue: Patient-Reported Outcome Use in Radiation Oncology Research and Routine Clinical Care.  
[https://www.mdpi.com/journal/curroncol/special\\_issues/Patient-Reported\\_Outcome\\_Use\\_in\\_Radiation\\_Oncology\\_Research](https://www.mdpi.com/journal/curroncol/special_issues/Patient-Reported_Outcome_Use_in_Radiation_Oncology_Research)
2. Associate Editor: Supportive Care in Cancer: Jan 2019 - current
3. Guest Editor (2014): Breast Diseases: A Year Book Quarterly 25(3): 234-5, 2014. Commentary

(g) *Reviewer (journal, agency, etc. including dates)*

**1. Panel Member**

- i. Biomedical/Clinical Research Review Panel, Michael Smith Foundation for Health Research (MSFHR): 2021
- ii. Biomedical/Clinical Research Review Panel, Michael Smith Foundation for Health Research (MSFHR): 2020

**2. External Referee for University Promotion**

- i. University of Toronto, Faculty of Medicine: Jun 2020

**3. External Grant reviewer:**

- i. Netherlands Organisation for Health Research and Development (ZonMw): Aug 2022
- ii. KWF Kankerbestrijding (Dutch Cancer Society): Jan 2022
- iii. UK Research and Innovation, Medical Research Council, Clinical Academic Research Partnership Round 3 Grant reviewer: Jan 2021
- iv. Cancer Research UK, Grant reviewer: July 2019
- v. Cancer Care Manitoba 2019 Operating Grant, Feb 2019
- vi. Swiss Cancer League Grant, External reviewer: Feb 2018
- vii. Cancer Research UK, Grant reviewer: Dec 2018

**4. Journal Reviewer**

**Journals = 65**

**Total Reviews = 224**

1. Lancet Oncology
  - a. Oct 2022
2. Frontiers in Oncology
  - a. Jun 2022
3. International Journal of Cancer and Clinical Research
  - a. Nov 2021
4. Cancer Control
  - a. Sep 2021
5. Translational Cancer Research
  - a. Jul 2021
6. Clinical Medicine Insights: Oncology
  - a. Jun 2021
  - b. Mar 2021

7. Cancers
  - a. Sep 2021 (2)
  - b. Aug 2021
  - c. Mar 2021
8. Journal of Patient Reported Outcomes
  - a. Jun 2022
  - b. Mar 2022
  - c. Dec 2021
  - d. Nov 2020
  - e. May 2020
9. Journal of Pain and Symptom Management
  - a. Apr 2020
10. Practical Radiation Oncology
  - a. Mar 2020
  - b. Jun 2020
11. International Journal of Integrative Care
  - a. Jan 2020
12. JAMA Oncology
  - a. Jan 2020
13. Lung Cancer Management
  - a. Nov 2019
14. CUREUS Journal of Medical Science
  - a. Apr 2020
  - b. Jan 2020
  - c. Aug 2019
15. Health and Quality of Life
  - a. April 2021
  - b. May 2019
16. Annals of Palliative Medicine
  - a. Feb 2019
17. BMC Palliative Care
  - a. Feb 2019
  - b. Dec 2018
18. European Journal of Cancer
  - a. Aug 2018
19. Clinical and Experimental Metastases
  - a. Aug 2018
  - b. Jun 2018
20. Cancer Management and Research
  - a. Aug 2018
  - b. Jun 2018
21. Head and Neck
  - a. Feb 2018
22. BMJ Open
  - a. Jul 2018
  - b. Jan 2018
  - c. Nov 2017
23. UBC Medical Journal
  - a. Nov 2017
24. Future Oncology
  - a. Oct 2017
25. Cancer Medicine
  - a. Sep 2017
26. Annals of Palliative Medicine
  - a. Aug 2017
27. Cancer
  - a. Aug 2017
28. BMC Health Services Research
  - a. May 2017
29. Advances in Radiation Oncology

- a. May 2017
- 30. Clinical Oncology
  - a. Jun 2021
  - b. Mar 2019
  - c. May 2017
- 31. Annals of Radiation Therapy and Oncology
  - a. May 2017
- 32. Cancer Epidemiology
  - a. Apr 2017
- 33. Annals of Clinical Case Reports
  - a. Apr 2017
- 34. Breast Cancer Research and Treatment
  - a. Mar 2017
- 35. Journal of Rural Health
  - a. Jun 2022
  - b. Apr 2022
  - c. Mar 2021
  - d. Feb 2017
- 36. British Journal of Cancer
  - a. Aug 2019
  - b. Jun 2019
  - c. Dec 2016
- 37. Canadian Family Physician
  - a. Jul 2016
- 38. Expert Review of Quality of Life in Cancer Care
  - a. Jun 2016
- 39. Clinical Cancer Research
  - a. Jun 2015
- 40. Radiotherapy and Oncology
  - a. Sep 2020
  - b. Mar 2015
- 41. QJM: An International Journal of Medicine
  - a. Mar 2015
- 42. BMC Research Notes
  - a. Jan 2015
  - b. Oct 2014
- 43. Psycho-Oncology
  - a. Feb 2017
  - b. Oct 2016
  - c. Jan 2015
  - d. Sep 2014
- 44. CMAJ Open
  - a. Nov 2020
  - b. Aug 2018
  - c. Sep 2017
  - d. Jun 2017
  - e. Mar 2017 (2)
  - f. Jul 2016
  - g. Aug 2014
- 45. BMC Cancer
  - a. Oct 2019
  - b. Jan 2019
  - c. Sep 2017
  - d. Aug 2017
  - e. Feb 2017
  - f. Dec 2015
  - g. Mar 2014
- 46. The Oncologist
  - a. Jan 2014
- 47. BMC Neurology

- a. Jan 2014
- b. Nov 2013
- 48. BMC Nursing
  - a. Mar 2014
  - b. Oct 2013
- 49. Current Oncology
  - a. Jul 2020
  - b. Jun 2019
  - c. Nov 2016
  - d. Oct 2016
  - e. Aug 2016
  - f. Oct 2015
  - g. July 2014
  - h. Feb 2014
  - i. Oct 2013
- 50. Canadian Medical Association Journal (CMAJ)
  - a. Dec 2021
  - b. Aug 2019
  - c. Oct 2017
  - d. Dec 2015
  - e. Jul 2015
  - f. Jun 2014
  - g. May 2014
  - h. Sep 2013
- 51. PLOS ONE
  - a. Jun 2015
  - b. Apr 2015
  - c. Sep 2013
- 52. Physicians' Services Incorporated Foundation (Resident Research Grant external reviewer)
  - a. April 2015
  - b. Aug 2013
- 53. Breast Cancer: Targets and Therapy
  - a. May 2013
- 54. Clinical Epidemiology
  - a. Jan 2013
- 55. Journal of Supportive Care in Cancer
  - a. May 2022
  - b. Mar 2022
  - c. Feb 2022
  - d. Dec 2021 (2)
  - e. Oct 2021
  - f. Mar 2021 (3)
  - g. Feb 2021
  - h. Jan 2021 (2)
  - i. May 2020
  - j. Jan 2020
  - k. Oct 2019
  - l. Feb 2019
  - m. June 2018
  - n. May 2018
  - o. Sep 2017
  - p. Jun 2017
  - q. Mar 2017
  - r. Dec 2016
  - s. Oct 2016 (2)
  - t. Nov 2015 (2)
  - u. Aug 2015
  - v. Jul 2015
  - w. May 2015
  - x. Dec 2014

- y. July 2014
- z. May 2014
- aa. Mar 2014
- bb. Feb 2014
- cc. Jan 2014
- dd. Nov 2013
- ee. Oct 2013
- ff. Jul 2013
- gg. May 2013
- hh. Apr 2013
- ii. Feb 2013
- jj. Jan 2013
- 56. Radiation Oncology
  - a. Mar 2015
  - b. Feb 2013
  - c. Oct 2012
  - d. Aug 2012
- 57. OncoTargets and Therapy
  - a. Mar 2017
  - b. Jan 2017
  - c. Aug 2016
  - d. Aug 2015
  - e. Jun 2014
  - f. May 2013
  - g. Aug 2012
- 58. Canadian Breast Cancer Foundation Research Grants
  - a. Jan 2014
  - b. Jun 2012
- 59. Nursing: Research and Reviews
  - a. Jun 2012
- 60. International Journal of General Medicine
  - a. Mar 2012
- 61. International Journal of Radiation Oncology, Biology, Physics
  - a. Sep 2022
  - b. Jun 2022
  - c. Feb 2022
  - d. Aug 2021
  - e. Nov 2020
  - f. Aug 2020
  - g. May 2020
  - h. Feb 2020
  - i. Jul 2019
  - j. Jun 2019
  - k. Feb 2019
  - l. Nov 2018
  - m. Aug 2018
  - n. May 2018
  - o. Feb 2018
  - p. Apr 2017
  - q. Mar 2017 (2)
  - r. Feb 2017
  - s. Dec 2016
  - t. Oct 2016
  - u. Jul 2016
  - v. Jun 2016
  - w. Dec 2015
  - x. Oct 2015
  - y. Aug 2015
  - z. Jun 2015
  - aa. May 2015

- bb. Jan 2015
- cc. Dec 2014
- dd. Sep 2014
- ee. Aug 2014
- ff. Apr 2014
- gg. Dec 2013
- hh. Jul 2013
- ii. Mar 2013
- jj. Feb 2012
- 62. Journal of Medical Imaging and Radiation Oncology
  - a. Mar 2015
  - b. Jan 2015
  - c. May 2014
  - d. Mar 2014
  - e. May 2013
  - f. Apr 2012
  - g. Feb 2012
  - h. Jan 2012
- 63. Journal of Cancer Epidemiology
  - a. Jun 2011
- 64. Annals of Surgical Oncology
  - a. Dec 2015
  - b. Nov 2015 (2)
  - c. Nov 2015 (1)
  - d. May 2011
- 65. Canadian Journal of Neurological Sciences
  - a. May 2013
  - b. Dec 2010
  - c. Jan 2010
  - d. Dec 2009
  - e. Aug 2009

(h) *External examiner (indicate universities and dates)*

1. Jean-Michel Lavoie, University of British Columbia (Interdisciplinary Oncology Program), Nov 27, 2019
2. Cassia Warren, University of British Columbia (Interdisciplinary Oncology Program), Jun 6, 2019

(i) *Consultant (indicate organization and dates)*

1. Canadian Partnership Against Cancer (represented BC Cancer Agency): Regional Consultation Session, March 1, 2012

(j) *Other service to the community*

1. Food and Drug Administration (FDA), USA: Expert Panelist. April 5 & 6, 2022.
2. Harvard School of Public Health: International Alumni Ambassador, 2012 - Present

### **13. AWARDS AND DISTINCTIONS**

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

1. Best Abstract in Clinical and Population-based Oncology, Canadian Association of Radiation Oncology, 2022
2. Dr. R.J. Finley Senior Scholar Award, UBC Department of Surgery, 2022



3. UBC Faculty of Medicine Outstanding Academic Performance award, 2022
4. UBC Faculty of Medicine Distinguished Achievement Award (Overall Excellence Mid-Career), 2021
5. 2019 Teamwork & Collaboration in Action Excellence Award, BC Cancer
6. Best Abstract in Survivorship, Canadian Association of Radiation Oncology, 2019
7. 2019 Radiation Oncology Institute Publication Award for best international publication in Radiation Oncology, American Society of Radiation Oncology (ASTRO), 2019.
8. Top 1% reviewers for Medicine, 2016 & 2017, www.publons.com
9. H. W. Johnson New Investigator Award, UBC Department of Surgery, 2015
10. Best Abstract in Supportive Care Award, Canadian Association of Radiation Oncology, 2014
11. Award in Support of Psychosocial Oncology Excellence, Brain Tumour Foundation of Canada, 2012
12. Jean Roy Memorial Award, Canadian Association of Radiation Oncology, 2010
13. Grace Shane Bursary, BC Cancer Agency, 2009 & 2010
14. APOS 2010 Fellowship, American Psychosocial Oncology Society, 2010
15. Residency Training Program Award for Best Research Project, BC Cancer Agency, 2008 & 2010
16. Award in Support of Psychosocial Oncology Excellence, Brain Tumour Foundation of Canada, 2009
17. John & Lorena Redekop Radiation Oncology Fellowship, BC Cancer Agency, 2009
18. Joseph Albert Award in Clinical Oncology, University of Calgary, 2004
19. Summer Studentship, Alberta Heritage Foundation for Medical Research, 2002
20. Undergraduate Merit Award, University of Calgary, 2002
21. Department of Biological Sciences Dean's List, University of Calgary, 2000 – 2002

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

(d) *Other Awards*

1. Healthier You Awards by the community of Prince George BC: Research Award in 2012 and 2018

#### **14. OTHER RELEVANT INFORMATION**

During my first decade as an independent researcher, I have developed a national and international reputation within radiation oncology, health services delivery, and clinical trials focused on metastatic disease. This is evidenced by my multiple invitations to review international journal manuscripts and grant competitions, with multiple repeat invites. My research has been selected for international press releases on multiple occasions through the American Society of Radiation Oncology (ASTRO) and the International Journal of Radiation Oncology, Biology, Physics, and my most recently completed clinical trials published in The Lancet, and the second recently published in JAMA Oncology.

## THE UNIVERSITY OF BRITISH COLUMBIA

### *Publications Record*

**SURNAME:** Olson

**FIRST NAME:** Robert  
**MIDDLE NAME(S):** Anton

**Initials:** RO  
**Date:** Jun 19, 2023

#### Authorship Statement:

*Key to my contribution:*

Underline indicates a trainee under my supervision

FA - First Author - typically performed the majority of the analyses in the manuscript, wrote the first draft

CA - Contributing Author – typically helped with experimental design, completed some analyses, edited the draft manuscript

SA - Senior Author – typically conceived the experimental approach, supervised the writing of the manuscript, corresponding author for the paper. In some circumstances this can be concurrent with FA, indicating I was both the author who conceived of the research project, but also performed the bulk of the analysis and the manuscript writing.

*Italicized* comments follow some papers for role clarification or impact statement

**5 most influential publications have bold and italicized descriptions below them**

Google Scholar Citations = 4793; h index = 32; i10 index = 64

#### 1. REFEREED PUBLICATIONS

##### (a) *Journals*

1. Shin Y, Chang JS, Kim Y, Shin SJ, Kim J, Kim TH, Liu M, **Olson R**, Kim JS, Sung W. Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease. *Frontiers in Oncology* 2023;13:1061881.
2. Hamilton S, Liu J, Holmes C, DeVries K, **Olson R**, Tran E, Berthelet E, Wu J, Chau N, Chan M, Thamboo A. Population-Based Long Term Outcomes for Squamous Cell Carcinoma of the Nasal Cavity. *American Journal of Clinical Oncology*. E-pub ahead of print Mar 8, 2023.
3. Cereno R, Mou B, Baker S, Chng N, Arbour G, Bergman A, Liu M, Schellenberg D, Matthews Q, Huang V, Mestrovic A, Hyde D, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Jiang W, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S, **Olson R**. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? A secondary analysis of the population-based phase II SABR-5 trial. Accepted to *Radiotherapy and Oncology* Feb 13, 2023.
4. **Olson R** and Palma D. Should stereotactic ablative radiotherapy be used for oligometastatic disease? *NEJM Evidence* 2022;1(12).
5. Chan J, Kalinda G, Turner A, Tobias J, Clarmont W, Delaney G, Penniment M, Hutton J, **Olson R**, Bourque JM, Brundage M, Rodin D, Slotman B, Yap ML. Radiotherapy and Indigenous peoples in Canada and Australia: building paths towards reconciliation in cancer care delivery. Accepted to *Int J Radiat Oncol Phys* Sep 28, 2022.
6. Kim J, Chang J, Sung W, Kim J, Kim T, Kim K, Ko H, Lee H, Shin S, Liu M, **Olson R**. A comparison of two disease burden assessment methods (3D volume versus the number of lesions) for prognostication of survival in metastatic melanoma: implications for the characterization of oligometastatic disease. *Int J Radiat Oncol Biol Phys* 2022;114(5);883-91.
7. Baker S, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, **Olson R**. Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. *Int J Radiat Oncol Biol Phys* 2022;114(5);849-55.
8. Benny A, Mclay M, Bates A, Callaghan R, **Olson R**. Population-based comparison of cancer survival outcomes in patients with and without psychiatric disorders. *BMC Psychiatry* 2022;22:543.
9. Duzenli C, Chan E, Koulis T, Lomas S, Singer J, Morris D, Spence J, Lee T, Burns, **Olson R**. Validation of the a patient-reported outcome measure for moist desquamation among breast radiotherapy patients. *Current Oncology* 2022;29(7):4734-47.

10. Baker S, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Mattews Q, Tyldesley S, **Olson R**. Predictors of early polymetastatic relapse following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis of the phase II SABR-5 trial. *Int J Radiat Oncol Biol Phys* 2022;114(5):856-61.
11. **Olson R**, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Mattews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. *JAMA Oncology*. JAMA Oncology. Published online September 29, 2022. doi:10.1001/jamaoncol.2022.4394  
***Population-based phase II trial that I am the Principal Investigator on, which is the most comprehensive assessment of toxicity from SABR for oligometastatic cancer published internationally, featured in multiple press releases.***
12. Urban R, Wong J, Lim P, Zhang S, Spadinger I, **Olson R**, Bachand F, Ho C, Tinker A, Gondara L, Hamilton S. Cervical Cancer Patient Reported Gastrointestinal Outcomes: Intensity/Volumetric Modulated Versus 3D Conformal Radiation Therapy. *Journal of Gynecological Oncology* 2022; 33(5):e70.
13. Duzenli C, Chan E, Bergman A, Grahame S, Singer J, Burns L, **Olson R**. A novel carbon-fibre adjustable reusable accessory (CARA) for supine breast positioning to reduce toxicity in breast adjuvant radiotherapy: a study protocol for a multicenter phase III randomized controlled trial. *BMC Cancer* 2022;22(1):673.
14. Sit D, Bale M, Lapointe V, **Olson R**, Hsu F. Association between EGFR or ALK mutation status and pain response to palliative radiation in non-small cell lung cancer. *Journal of Thoracic Surgery* 2022;3(8):100371.
15. Barry A, Helou J, Bezjak A, Wong R, Dawson L, Ringash J, Fazelzad R, Liu Z, **Olson R**, Palma D, Ost P, Siva S, Philips R, Adhikari N. Quality of life outcomes following stereotactic body radiotherapy in patients with oligometastatic diseases: A Systematic Review and Meta-Analysis. Accepted to *Radiotherapy and Oncology*, May 30, 2022.
16. Harrow S, Palma D, **Olson R**, Gaeda S, Louie A, Haasbeek, Mulroy L, Lock M, Rodriguez G, Yaremko B, Schelleberg D, Ahmed B, Senthil S, Swaminath A, Kopeck N, Liu M, Schlijper R, Bauman G, Senan S. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET) – extended long term outcomes. *Int J Radiat Oncol Biol Phys* 2022;114(4):611-6.
17. Baker S, Jiang W, Mou B, Lund C, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chng N, Mattews Q, Benny A, Tyldesley S, **Olson R**. Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis from the population-based phase II SABR-5 trial. *Int J Radiat Oncol Biol Phys* 2022;114(4):617-26.
18. Caissie A, **Olson R**, Barbera L, O'Donnell J, Davis C-A, Croke J, Bird L, Kildea J, Brown E, Brundage M, Milosevic M. Striving to fill in gaps between clinical practice and standards: the evolution of a Pan-Canadian approach to PRO use. *Current Oncology* 2022; 29:3698-3707.
19. Chan M, **Olson R**, Lapointe V, Hamm J, Bachand F, Holloway C, Parsons C, Lim C. Using a weekly patient-reported outcome questionnaire to track acute toxicity in patients undergoing pelvic radiotherapy for gynecologic cancers. *Current Oncology* 2022;29:3306-3317.
20. Yan L, Nichol A, **Olson R**. Validation of the BC-brain patient reported outcome questionnaire for patients with central nervous system tumours treated with radiotherapy. *Current Oncology* 2022; 29:2798-2807. SA
21. **Olson R**, LaPointe V, Benny A, Chan M, Lefresne S, McKenzie M. Evaluation of patient reported outcome differences by radiotherapy technique for bone metastases in a population-based health care system. *Current Oncology* 2022; 29(3), 2073-2080. FA & SA
22. Urban R, Alfaraj F, **Olson R**, Berthelet E, Tran E, Wu J, Hamm J, Hamilton S. The Prognostic Impact of Radiotherapy Delays in Oropharynx Carcinoma and the Role of p16 Status. *American Journal of Clinical Oncology* 2022;45(3):122-8. CA 15%.
23. Van Oirschot M, Palma D, Chng N, Senan S, Bergman A, Ward L, Huang V, Symes K, Chomas C, Bowes D, Harrow S, **Olson R**, Warner A, Verbakel W, Gaede S. Determining planning priorities for stereotactic ablative radiotherapy (SABR) for oligometastatic disease: A secondary analysis of the SABR-COMET Randomized Trial. *Int J Rad Oncol Biol Phys* 2022;114(5):1016-21.
24. **Olson R**, McLay M, Hamm J, Callaghan. Identification of tobacco-related cancer diagnoses among individuals with psychiatric disorders: a population based, matched cohort study using a competing-risks approach from British Columbia. *Curr Oncol* 2021; 28(6):4953-60. FA & SA

25. Hamilton S, Chau N, Berthelet E, Wu J, Tran E, Chevrier M, Lau V, Chan M, DeVries K, Lapointe V, **Olson R**. Patient reported outcomes and complications during Head & Neck Cancer radiotherapy before versus during the COVID-19 Pandemic. *Supportive Care in Cancer* 2022;30(3):2745-53. SA
26. Sit D, Zhao B, Chen, KT, Lohrisch C, **Olson R**, Nichol A, Hsu F. The effect of breast cancer subtype on symptom improvement following palliative radiotherapy for bone metastases. *Clinical Oncology* 2022;34(4):267-73. CA 20%
27. Schlijper-Bos, Roel, Bos S, Hamilton S, Tran E, Berthelet, Wu J, **Olson R**, 90-day mortality after radiotherapy for head and neck cancer: a population-based comparison between rural and urban patients. *Head and Neck* 2021; 43(11): 3306-13. SA
28. Jasper K, Matthews Q, Liu B, **Olson R**. Evidence-based planning target volume (PTV) margin reduction for modern lung stereotactic ablative radiotherapy (SABR) using deformable registration. *Advances in Radiation Oncology* 2021;6(6):100750. SA
29. O'Reilly E, Peacock M, **Olson R**. Access to cancer radiotherapy: the effects of geography and rurality on patient choice of treatment. *UBCMJ* 2021;12.2(33-4). SA.
30. Sit D, Koh W, Shokoohi A, Tran E, **Olson R**, Wu J Berthelet E, Baycraf T, Vu M, Hamm J, Hamilton S. External beam radiotherapy in pT4 well-differentiated thyroid cancer: A population based study of 405 patients. *Int J Radiat Oncol Biol Phys* 2021;111(2):468-78. CA 5%
31. Qu M, Chen U, Zaric G, Senan S, **Olson R**, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senthil S, Swaminath A, Kopek N, Liu M, Warner A, Rodrigues G, Palma D, Louie A. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET randomized trial. *Int J Radiat Oncol Biol Phys* 2021;109(5): 1176-1184. CA 5%
32. Lefresne S, Giambattista J, Ingledew P, Carolan H, **Olson R**, Loewen S. Radiation Oncology resident and program director perceptions on the job market and impact on well being. *Cureus* 2020;12(3):e7187. CA 5%
33. Chan M, Ni Mhurchu E, Yuan R, Gondara L, Mckenzie M, **Olson R**, Thiessen B, Lalani N, Ma R, Nichol A. Patients with Pretreatment Leukoencephalopathy and Older Patients have More Cognitive Decline after Whole Brain Radiotherapy. *Radiation Oncology* 2020;15:271. CA 5%
34. Hamilton S, Tran E, Ho C, Berthelet E, Wu J, DeVries K, LaPointe V, Bowman A, Lagman M, **Olson R**. Patient reported outcome measures in patients undergoing radiotherapy for Head & Neck cancer. *Journal of Supportive Care in Cancer* 2021;29:2537-47. SA (Citations 4)
35. Hamilton S, Yin Y, Wu J, Tran E, Berthelet E, Chau N, Liu A, **Olson R**. Population-based Outcomes by Immunosuppressed Status in Patients Undergoing Radiotherapy for Oropharyngeal Cancer. *Radiotherapy and Oncology* 2020;151:110-7. SA (Citations 2).
36. Koullis T, Truong P, Nichol A, Tyldesley S, Weir L, Speers C, Gondara L, **Olson R**, Hypofractionated Adjuvant Radiotherapy is Effective for Patients with Lymph Node Positive Breast Cancer: A Population-Based Analysis. *International Journal of Radiation Oncology Biology Physics* 2020;108(5):1150-8. SA. (Citations 8)
37. Chan M, **Olson R**, Lefresne S, McKenzie. Advanced Radiation Therapy Use in the Treatment of Bone Metastases in a Public Salary-Funded Non-Incentivized Healthcare System. *JCO Oncology Practice* 2020;17(2). CA 30%
38. Challapalli A, Aziz S, Kumar A, **Olson R**, Ashford R, Gabbar O, Rai B, Bahl A. Spine and non-spine bone metastases – current controversies and future directions. *Clinical Oncology* 32;728-44. 2020. CA 15% (Citations 6)
39. Ahmed S, Barbera L, Bartlett SJ, Bebb DG, Brundage M, Bryan S, Cheung WY, Coburn N, Crump T, Cuthbertson L, Howell D, Klassen AF, Leduc S, Li M, Mayo NE, McKinnon G, **Olson R**, Pink J, Robinson JW, Santana MJ, Sawatzky R, Moxam RS, Sinclair S, Servidio-Italionia F, Temple W. A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes. *Current Oncology* 2020;27(2):90-9. CA 5% (Citations 5)
40. Oh J, Tran E, Berthelet E, Wu J, **Olson R**, Bowman A, Reynolds C, Liu A, Hamilton S. Association between Nutritional Risk Index and Outcomes for Head and Neck Cancer patients receiving Concurrent Chemo-Radiotherapy. *Head & Neck* 2020;42(9):2560-70. CA 10%
41. Palma D, **Olson R**, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, yaremko B, Schellenberg D, Ahmad B, Senthil S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Schlijper R, Bauman G, Laba J, Qu X, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. *Journal of Clinical Oncology (JCO)* 2020;38(25):2830-8. CA 25% (IF 44.54; Citations 229)
42. **Olson R**, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, Harrow S, Correa R, Bhat V, Pai H, Mohamed I, Miller S, Schneiders F, Laba J, Wilke D, Senthil S, Louie A, Swaminath A, Chalmers A, Gaede S, Warner A, de G, T, Allan A, Palma D. Stereotactic Ablative Radiotherapy for the

Comprehensive Treatment of 1-3 Oligometastatic Tumors (SABR-COMET-3): Study Protocol for a Randomized Phase III Trial. *BMC Cancer* 20:380, 2020. FA and SA. (Citations 19)

***International phase III trial that I developed and that I am the PI on, as a follow up to SABR-COMET published in the Lancet (see Palma et al 2019 below). Radio interview on CBC Daybreak North Jan 14, 2021. <https://www.cbc.ca/listen/live-radio/1-109-daybreak-north> at 1:18:00 - 1:23:00***

43. Urban R, Wu J, **Olson R**, Tran E, Berthelet E, DeVries K, Wilson D, Godoy T, Hamilton S. FDG-PET/CT Scan Assessment of Response 12 weeks post Radical Radiotherapy in Oropharynx Head and Neck Cancer: The Impact of p16 Status. *Radiotherapy and Oncology* 2020; 128:14-20. (CA 10%; Citations 4)
44. Howard AF, Medhurst K, Manhas D, Yang L, Brown S, **Olson R**. The Usefulness of patient-reported outcomes and the influence on palliative oncology patients and health services: A qualitative study on the Prospective Outcomes and Support Initiative (POSI). Accepted to *Cancer Nursing* March 2, 2020. SA.
45. Chan J, Polo A, Zubizarreta E, Bourque J-M, Sheppard A, **Olson R**, Dennis K, Brundage M, Slotman B, Abdel-Wahab M. Examining geographic accessibility to radiotherapy in Canada and Greenland for indigenous populations: measuring inequities to inform solutions. *Radiotherapy and Oncology* 2020; 146:1-8. (CA 10%; Citations 4).
46. **Olson R**, Schlijper R, Chng N, Matthews Q, Arimare M, Mathews L, Hsu F, Berrang T, Louie A, Mou B, Valev B, Laba J, Palma D, Schellenberg D, Lefresne S. SUPR-3D: A Randomized Phase III Trial Comparing Simple Unplanned Palliative Radiotherapy versus 3D Conformal Radiotherapy for Patients with Bone Metastases: Study Protocol. *BMC Cancer* 2019;19:1011. FA&SA (Citations 3)
47. Schlijper R, Fraser I M, Regan J, Lefresne S, **Olson R**. (September 07, 2019) Patterns of Radiotherapy Utilization for Lung Cancer Patients with Brain Metastases: A Population-based Analysis. *Cureus* 11(9): e5591. doi:10.7759 (SA; Citations 6)
48. Palma D, **Olson R**, Harrow S, Correa R, Schneider F, Haasbeek C, Rodrigues G, Lock M, Yaremko B, Bauman G, Ahmad B, Schellenberg D, Liu M, Gaede S, Laba J, Mulroy L, Senthil S, Louie A, Swaminath A, Chalmers A, Warner A, Slotman B, Grujil T, Allan A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET-10): Study Protocol for a Randomized Phase III Trial. *BMC Cancer* 2019;19: 816. CA 10% (Citations 76)
49. **Olson R**, Senan, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments in the Oligometastatic Setting. *International Journal of Radiation Oncology, Biology, Physics* 2019; 105(5): 943-7. FA (IF 6.203 ; Citations 23)
50. Fraser I, Lefresne S, Regan J, Berthelet E, Chooback N, Ho C, **Olson R**. Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis. *Lung Cancer* 2019; 13:97-103. SA (IF 5.705; Citations 4)
51. Chan J, Polo A, Zubizarreta E, Bourque J-M, Sheppard A, **Olson R**, Dennis K, Brundage M, Slotman B, Abdel-Wahab M. Disparities in access to radiation therapy for regions inhabited by a higher proportion of First Nations, Inuit and Metis populations in Canada, and its association with cancer outcomes. *Applied Radiation Oncology* June 2019. (CA 5%)
52. Oh J, Prisman E, **Olson R**, Berthelet E, Wu J, Tran E, Bados B, Kaviani R, Hamilton S. Primary organ preservation versus total laryngectomy for T4a larynx cancer. *Head and Neck cancer* 2019;41:3265–75. CA 15% (IF 2.442)
53. Palma D, **Olson R**, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard-of-care palliative treatment in patients with oligometastatic cancer (SABR-COMET): a randomized, phase II, open-label trial. *The Lancet* 2019;393(10185;2051-8). CA 25% (IF 59.102; Citations 938)

***This paper was the subject of editorial comments in the same issue of The Lancet. It is the first randomized trial to suggest a potential survival advantage to stereotactic ablative radiotherapy in the oligometastatic setting, and led to several follow-up international phase III trials I am leading or co-leading. It received the 2019 Radiation Oncology Institute Publication Award for publication of the year, and is considered a Landmark publication in Radiation Oncology.***

54. Baker L, **Olson R**, Braich T, Koulis T, Ye A, Ahmed N, Tran E, Lawyer K, Otto K, Smith S, Mestrovic A, Matthews Q. Real-time interactive planning for radiotherapy of head and neck cancer with volumetric modulated arc therapy. *Physics & Imaging in Radiation Oncology* 2019; 9:83-8. CA 30%
55. Fraser I, Lefresne S, Regan J, Berthelet E, Chooback N, Ho C, **Olson R**. Palliative thoracic radiotherapy near the end of life in lung cancer: a population-based analysis. *Lung Cancer* 2019;135:91-103. SA (IF 3.958; Citations 4)
56. Parimi S, Tyldesley S, **Olson R**, Chi K, Bondy S, McKenzie M, Duncan G, Lapointe V, Abraham A, Pai H, Bachand F. Pain response in a Population-based study of Radium-223 (Ra223) for Metastatic Castration Resistant Prostate Cancer (CRPC). *Canadian Urological Association Journal* 2019;13(10):E311-6. CA 5%
57. McKenzie E, Zaki P, Raman S, **Olson R**, McFarlane T, DeAnglis, Chan S, Pidduck W, Razvi Y, Bushehri A, Chow E. Radiation-induced nausea and vomiting: A comparison between MASCC/ESMO, ASCO and NCCN antiemetic guidelines. *Supportive Care in Cancer* epub Jan 3, 2019. CA 5% (IF 2.698; Citations 14)
58. **Olson R**, Liu M, Bergman A, Lam S, Hsu F, Mou B, Berrang T, Mstrovic A, Chng N, Hyde D, Matthews Q, Lund C, Glick D, Pai H, Basran P, Carolan H, Valev B, Lefresne S, Tyldesley S, Schellenberg D. Population-based Phase II trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: SABR-5. *BMC Cancer* 2018 18:954. FA & SA (IF 3.288; Citations 5)
59. Dosani M, Yang R, Wilson D, Liu M, Yong-Hing C, Hamm J, Lund C, **Olson R**, Schellenberg D. Metabolic tumor volume is prognostic of local control, overall survival, and disease-free survival in patients with non-small cell lung cancer treated with stereotactic ablative radiotherapy. *Current Oncology* 2019;26(1):e57-63. CA (IF 2.048; Citations 17)
60. **Olson R**, Chan M, Minhas N, Kandola G, Tiwana M, Lefresne S, Halperin R, Schellenberg D, Wai E, Ahmed N, Tyldesley S. Programmatic comparison and dissemination of an audit of single fraction radiotherapy prescribing practices for bone metastases is associated with a meaningful and lasting change in practice on a population level. *Int J Radiat Oncol Biol Phys* 2018;102(2):325-9. SA (IF 6.203; Citations 5)

***Last paper in a series demonstrating how population-based comparative effectiveness research can lead to a lasting meaningful change in practice. See Olson IJROBP 2016 & Olson IJROBP 2014 below.***

61. Hamilton S, Tran E, Wu J, Berthelet E, **Olson R**. Early (90-Day) Mortality after Radical Radiotherapy for Head & Neck Squamous Cell Carcinoma: A Population-Based Analysis. *Head & Neck* 2018; 40(11); 2432-40. SA (IF 2.442; Citations 5)
62. Cassie A, Brown E, **Olson R**, Barbera L, Davis C-A, Brundage M, Milosevic M. Improving Patient Outcomes and Radiotherapy Systems: A Pan-Canadian Approach to Patient Reported Outcome Use. *Medical Physics* 2018; 45 (10):e841-4. CA 20% (IF 2.884; Citations 3)
63. Koulis T, Dang A, Speers C, **Olson R**. Factors affecting radiotherapy prescribing practices in the post-mastectomy setting. *Current Oncology* 2018 Apr;25(2)e-146-51. SA (IF 2.048; Citations 5)
64. Howard, A.F., Kazanjian, A., Newton, K., Pritchard, S., **Olson, R.** Hasan, H., Goddard, K.. Healthcare system barriers to long-term follow-up for adult survivors of childhood cancer in British Columbia, Canada: A qualitative study. *Journal of Cancer Survivorship* 2018;12(3)277-90. CA 10% (IF 3.303; Citations 13)
65. Chaudhry A, Koulis T, Speers C, **Olson R**. Prescribing practices of endocrine therapy for ductal carcinoma in situ in British Columbia. *Current Oncology* 2018 Apr;25(2) 133-38. SA (IF 2.048)
66. Dang A, Miller S, Horvat D, Klassen-Ross T, Graveline M, Collins R, **Olson R**. Assessing post radiotherapy handover notes from a family physician perspective. *Current Oncology* 2018;25(1):49-52 . SA (IF 2.048)
67. Hasan H, Yu J, Taguchi K, Samargandit OA, Howard F, Lo A, **Olson R**, Goddard K. Assessing the Methodological Quality of Systematic Reviews in Radiation Oncology: A systematic review. *Cancer Epidemiology* 2017;50(Pt A):141-9. CA 10%. (IF 2.619; Citations 18)
68. Yang L, Manhas D, Howard F, **Olson R**. Patient reported outcome use in oncology: A systematic review of the impact on patient-clinician communication. *Supportive Care in Cancer* 2018;26(1):41-60 . SA (IF 2.698; Citations 106)

***I co-supervised two medical students on this systematic review on a topic I am a recognized international expert in: Patient Reported Outcome (PRO) use in oncology.***

69. Lefresne S, **Olson R**, Cashman R, Kostuik P, Jiang WN, Levy K, McKenzie M, Hulstyn A, Liu M, Wu J, Berthelet E. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic. *Lung Cancer* 2017;112:35-40. CA 25%. (IF 3.958 ; Citations 6)

70. McLay M, Stedford A, Yurkowski E, Matlock S, Cheung W, Tran E, Berthelet E, Wu J, **Olson R**. Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program. *Radiotherapy and Oncology* 2017;124(1):174-81. SA (IF 5.252)
71. **Olson R**, Howard F, Lapointe F, Schellenberg D, Nichol A, Bowering G, Curtis S, Walter A, Brown S, Thompson C, Bergin J, Lomas S, French S, Halperin R, Tyldesley S, Beckham. Provincial development of a patient reported outcome initiative to guide patient care, quality improvement, and research. *Healthcare Management Forum* 2018; 31(1)13-17. FA & SA (Citations 10)
72. Koulis T, Beecham K, Speers C, Tyldesley S, Voduc D, Simmons C, **Olson R**. Neoadjuvant systemic therapy in breast cancer; utilization and radiotherapy practice trends. *Current Oncology* 2017;24(5):310-7. SA. (IF 2.048; Citations 4)
73. Kim J, Chang J, Maghaddamjou A, Kornelsen E, Ruan J, **Olson R**, Cheung W. Asian and non-Asian disparities in outcomes of non-nasopharyngeal head and neck cancer. *The Laryngoscope* 2017;127(11):2528-2533. CA 5%. (IF 2.442; Citations 5)
74. Dang A, Horvat D, Klassen-Ross T, Collins R, Graveline M, **Olson R**. Evaluation and improvement of radiation oncology therapy completion note. *BC Medical Journal* 2017;59(6):312-6. SA
75. Vodermaier A, Lucas S, Linden W, **Olson R**. Anxiety after diagnosis predicts lung-cancer specific and overall survival in patients with stage III non-small cell lung cancer. A population-based cohort study. *Journal of Pain and Symptom Management* 2017;53(6):1057-65. SA (IF 3.249; Citations 43)
76. McCull R, McGahan C, Cai E, **Olson R**, Cheung W, Raval M, Phan T, Karimuddin A, Brown C. Impact of hospital volume on quality indicators for rectal cancer surgery in British Columbia, Canada. *American Journal of Surgery* 2017;213(2): 388-394. CA 5% (IF 2.403 ; Citations 10)
77. Conway J, Yurkowski E, Glazier J, Gentles Q, Walter A, Bowering G, Curtis S, Schellenberg D, Halperin R, Lapointe V, Beckham W, Olivotto I, **Olson R**. Comparison of patient-reported outcomes with single versus multiple fraction palliative radiotherapy for bone metastases in a population-based cohort. *Radiotherapy and Oncology* 2016;119:202-7. SA (IF 5.252; Citations 29)
78. Tiwana M, Barnes M, Kiraly A, **Olson R**. Utilization of palliative radiotherapy for bone metastases near end of life in a population-based cohort. *BMC Palliative Care* 2016;15:2. SA (IF 2.922; Citations 24)
79. Barnes M, Tiwana M, Miller S, Kiraly A, Olivotto I, Emmons, S, **Olson R**. Palliative radiotherapy fractionation schedules prescribed are dependent on the distance a patient travels to receive treatment. *Radiotherapy and Oncology* 2015;117(2):390-2. SA (IF 5.252; Citations 4)
80. Tiwana M, Barnes M, Yurkowski E, Roden K, **Olson R**. Incidence and treatment patterns of complicated bone metastases in a population based radiotherapy program. *Radiotherapy and Oncology* 2016;118(3):552-6. SA (IF 5.252; Citations 20)
81. Nichol A, McKenzie M, Ma R, Cheung A, Schellenberg D, Peacock M, Vellani R, Vollans E, Bergman A, Hsu F, Germain F, Gondara L, **Olson R**, Carolan, H. Volumetric radiosurgery for 1 to 10 brain metastases: a multi-centre, single-arm, phase 2 study. *Int J Radiat Oncol Biol Phys* 2016;94(2):312-21. CA 10% (IF 6.203; Citations 37).
82. Barnes M, Tiwana M, Kiraly A, Hutchison M, **Olson R**. Incidence of distal bone metastases in patients treated for palliative radiotherapy and associations with primary tumour type. *Journal of Bone Oncology* 2015 4(4): 107-9. SA (IF 2.866; Citations 9)
83. Rodin D, Grover S, Xu M, Hanna T, **Olson R**, Schreiner J, Momex F, Palma D, Gaspar L. Radiotherapeutic management of non-small cell lung cancer in the minimal resource setting. *J Thorac Oncol* 2016 11(1) 21-9. CA (IF 12.46; Citations 11)
84. **Olson R**, Tiwana M, Barnes M, Cai E, McGahan C, Roden K, Yurkowski E, Gentles Q, French J, Halperin R, Olivotto I. Impact of using audit data to improve evidence based utilization of single fraction radiotherapy for bone metastases in British Columbia. *Int J Radiat Oncol Biol Phys* 2016;94(1):40-7. FA (IF 6.203; Citations 27).

***Second paper in a series demonstrating how population-based comparative effectiveness research can lead to a change in practice. (see Olson et al. 2014 below, and Olson et al 2018 above, both with italicized comments)***

85. Olivotto IA, Soo J, **Olson R**, Rowe MA, French J, Jensen B, Pastuch A, Halperin R, Truong P. Patient preferences for timing and access to radiation therapy. *Current Oncology* 2015 22(4):279-86. CA 10% (IF 2.048; Citations 3)
86. Lo A, **Olson R**, Feldman-Stewart, Truong P, Parsons C, Bottorff J, Carolan H. A patient-centred approach to evaluate the information needs of women with ductal carcinoma in situ. *American Journal of Clinical Oncology* 2017;40(6):574-81. CA *For this manuscript I co-supervised the senior resident first author, and contributed to analysis and manuscript writing.* (IF 3.062; Citations 16)
87. Hamilton S, Tyldesley S, Speers C, Li D, **Olson R**, McBride M. Second malignancies after adjuvant

- radiotherapy for early stage breast cancer: Is there an increased risk with the addition of regional radiation to local radiation? *Int J Radiat Biol Phys* 2015;91(5):977-85. CA 20%(IF 6.203; Citations 21).
88. Ye A, Cheung W, Goddard K, Horvat D, **Olson R**. Follow-up Patterns of Cancer Survivors: A Survey of Canadian Radiation Oncologists. *J Cancer Surviv* 2015 9:388-493. (IF 3.303; Citations 5).
  89. Lefresne S, Berthelet E, Cashman R, Levy K, Liu M, Carolan H, McKenzie M, Kostuik P, **Olson R**. The Vancouver Rapid Access Clinic for Palliative Lung Radiation: Providing More than Just Rapid Access. *Supportive Care in Cancer* 2015;23:125-32. SA (IF 2.698; Citations 20)
  90. Cao J, Truong P, Olivotto I, **Olson R**, Coulombe G, Keyes M, Weir L, Gelmon K, Bernstein V, Woods R, Speers C, Tyldesley S. Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-year outcomes of a population-based cohort. *Int J Radiat Oncol Biol Physics* 2014;90(3):509-17. CA 20%(IF 6.203; Citations 36).
  91. **Olson R**, Tiwana M, Barnes M, Kiraly A, Beecham K, Miller S, Hoegler D, Olivotto I. Use of single versus multiple fraction palliative radiotherapy for bone metastases: Population-based analysis of 16,898 courses in a Canadian Province. *Int J Radiat Oncol Biol Physics* 2014; 89:1092-9. FA & SA (IF 6.203; Citations 60)
 

*First paper in a series demonstrating how population-based comparative effectiveness research can lead to a change in practice. This initial assessment demonstrated a large variation in practice across BC, with evidence supporting a strong effect of the culture of prescriber's practicing centre.*
  92. Tiwana M, Wu J, Hay J, Wong F, Cheung W, **Olson R**. 25 year survival outcomes for squamous cell carcinoma of the head and neck: population-based outcomes from a Canadian province. *Oral Oncology* 2014;50:651-6. SA (IF 4.794; Citations 61)
  93. Lo A, Liu M, Chan E, Lund C, Truong P, Loewen S, Cao J, Schellenberg D, Carolan H, Berrang T, Wu J, and **Olson R**. The impact of peer review of structure contouring in Stereotactic body radiation therapy (SBRT) planning for primary lung cancer: a multi-center quality assurance study. *J Thorac Oncol* 2014;9(4):527-33. SA (IF 12.460; Citations 19)
  94. Tiwana M, Wu J, Hay J, Wong F, Cheung W, **Olson R**. Incidence of second metachronous head and neck cancers: population-based outcomes from a Canadian province over 25 years. *Laryngoscope* 2014;124:2287-91. SA (IF 2.442; Citations 30)
  95. Howard F, Smillie K, Turnbull K, Munroe D, Ward A, Kazanjian A, **Olson R**. Access to Medical and Supportive Care for Rural and Remote Cancer Survivors in Northern British Columbia. *The Journal of Rural Health* 2014;30:311-21. SA (IF 1.453; Citations 44)
  96. Vodermaier A, Linden W, Rnic K, Young S, Ng A, Ditsch N, **Olson R**. Prospective associations of depressions with survival: A population-based cohort study in patients with newly diagnosed breast cancer. *Breast Cancer Res Treat* 2014 143(2):373-84. SA (IF 3.940; Citations 69)
  97. Howard F, Hasan H, Bobinski MA, Nurcombe W, **Olson R**, Parkinson M, Goddard K. Parents Perspectives of Life Challenges Experienced by Long-Term Paediatric Brain Tumour Survivors: Work and Finances, Daily and Social Functioning, and Legal Difficulties. *Journal of Cancer Survivorship: Research and Practice* 2014 8:372-83. CA 10%.. (IF 3.303; Citations 11)
  98. Howard F, Tan de Bibiana J, Smillie K, Goddard K, Pritchard S, **Olson R**, & Kazanjian A. Trajectories of social isolation in adult survivors of childhood cancer. *Journal of Cancer Survivorship: Research and Practice* 2014 8(1):80-93. CA. (IF 3.303; Citations 48)
  99. **Olson R**, Howard F, Turnbull K, Munroe D, Zirul C, Manji R, Tobin P, Ward A. Prospective evaluation of unmet needs of rural & aboriginal cancer survivors in northern British Columbia. *Current Oncology* 2014;21(2):e179-85. FA & SA (IF 2.048; Citations 16)
  100. Davidson A, Chia S, **Olson R**, Nichol A, Speers C, Coldman A, Bajdik C, Woods R, Tyldesly S. Population-based stage, treatment and outcomes cohort study for patients diagnosed with breast cancer in British Columbia in 2002. *CMAJ Open* 2013;1(4) E134-41. CA. *I was heavily involved in developing the database and editing this manuscript, and was the FA on a related publication listed below in the Can J Public Health.* (IF 6.8; Citations 27)
  101. Lund C, Cao J, **Olson R**, Halperin R, Liu M. The distribution and patterns of practice of stereotactic ablative body radiotherapy in Canada. *Journal of Medical Imaging and Radiation Sciences* 2014;45(1):8-15. CA 10% (IF 1.109; Citations 9)
  102. **Olson R**, Karam I, Wilson G, Bowman A, Lee C, Wong F. Population based comparison of two feeding tube approaches for head & neck cancer patients receiving concurrent systemic-radiation therapy: Is a prophylactic feeding tube approach harmful or helpful? *Supportive Care in Cancer* 2013; 21: 3433-9. FA & SA (IF 2.698; Citations 36)
  103. Cao J, **Olson R**, Tyldesley S. Comparison of Recurrence and Survival Rates between Breast-Conserving Therapy and Mastectomy in Young Women with Breast Cancer. *Current Oncology* 2013;



- 20(6): e593-601. CA. *I was a co-supervisor of the FA who was a fellow working with me, and was involved in all aspects of the study design and publication.* (IF 2.048; Citations 74)
104. Lefresne S, Olivotto I, Jo H, Blood P, and **Olson R**. Impact of Quality Assurance Rounds in a Canadian Radiotherapy Department. *Int J Radiat Oncol Biol Phys* 2013; 85 (3) e117-121. SA (IF 6.203; Citations 46)
  105. Palma D, Haasbeek C, Rodrigues G, Dachele M, Lock M, Yaremko B, **Olson R**, Liu M, Panarotto J, Griffioen G, Gaede S, Slotman B, Senan S. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. *BMC Cancer* 2012; 12 (1) 305. CA. *I was the provincial principal investigator in BC for this study, and was involved in changes to the protocol, patient accrual, and this manuscript.* (IF 3.288; Citations 149)
  106. Lengoc S, Soo J, McGahan C, French J, Tyldesley S, **Olson R**. Referral Patterns of Patients for Palliative Radiation Therapy in British Columbia: A Comparison Between Rural and Urban Family Physicians. *Journal of Medical Imaging and Radiation Sciences* 2012; 43: 161-7. SA (IF 1.109; Citations 6)
  107. **Olson R**, Lengoc S, Tyldesley S, French J, McGahan C, Soo J. Relationships between family physicians' referral for palliative radiotherapy, knowledge of radiotherapy indications, and prior training: a survey of rural and urban physicians. *Radiation Oncology* 2012; 7(73). FA & SA (IF 3.098; Citations 19)
  108. **Olson R**, Caon J, Tyldesley S, Bergman A, Bobinski M A, Fong M, Vellani R, Goddard K. National survey of health care providers' views on the risk of inadvertent exposure of pregnant patients to ionizing radiation in Canadian radiotherapy departments. *J Radiat Oncol* 2012; 1(1): 81-5. FA (IF 3.098; Citations 1)
  109. Kosztyla R, **Olson R**, Carolan H, Balkwill S, Moiseenko V, Kwan W. Evaluation of dosimetric consequences of seroma contour variability in accelerated partial breast irradiation using a constructed representative seroma contour. *Int J Radiat Oncol Biol Phys* 2012;84:527-32. CA 30%(IF 6.203; Citations 18)
  110. **Olson R**, Woods R, Speers C, Lau J, Lo A, Truong P, Tyldesley S, Olivotto I, Weir L. Does the intent to irradiate the internal mammary nodes impact survival in women with breast cancer? A population based analysis in British Columbia. *Int J Radiat Oncol Biol Phys* 2012; 83(1):e35-41. FA & SA (IF 6.203; Citations 34)
  111. Caon J, **Olson R**, Tyldesley S, Bergman A, Bobinski M, Fong M, Ma V, Vellani R, Goddard K. Assessing the risk of inadvertent radiation exposure of pregnant patients during radiation therapy planning and treatment in British Columbia. *Practical Radiation Oncology* 2012; 2(3):179-85. CA. *Along with the SA (Goddard), we developed this project at the BC Cancer Agency, which subsequently resulted in the standard assessment of potential for pregnancy prior to radiotherapy planning or delivery, as well as impacting national guidelines.* (IF 2.794 ; Citations 3)
  112. **Olson R**, Nichol A, Caron N, Olivotto I, Speers C, Chia S, Davidson A, Coldman A, Bajdik C, Tyldesley S. Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomes. *Can J Public Health* 2012;103(1):46-52. FA & SA (IF 1.488; Citations 39)
  113. **Olson R**, Bobinski MA, Ho A, Goddard K. Oncologists' views of informed consent and shared decision making in paediatric radiation oncology. *Radiotherapy & Oncology* 2012;102:210-13. FA (IF 5.119; Citations 12)
  114. **Olson R**, Brastianos P, Palma D. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-analysis. *Journal of Neuro-Oncology* 2011;105(2):325-35. FA & SA (IF 3.060; Citations 78)
  115. **Olson R**, Iverson G, Carolan H, Parkinson M, Brooks B, McKenzie M. Prospective comparison of two cognitive screening tests: Diagnostic accuracy and correlation with community integration and quality of life. *Journal of Neuro-Oncology* 2011;105(2):337-44. FA & SA (IF 3.060; Citations 48)
  116. **Olson R**, Tyldesley S, Carolan H, Parkinson M, Chhanabhai T, McKenzie M. Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases. *Supportive Care in Cancer* 2011;19(11):1849-55. FA & SA (IF 2.698; Citations 70)
  117. **Olson R**, Hung G, Bobinski M A, Goddard K. Prospective evaluation of legal difficulties and quality of life in adult survivors of childhood cancer. *Pediatr Blood Cancer* 2011;56:437-43. FA (IF 2.634; Citations 18)
  118. **Olson R**, Parkinson M, McKenzie M. Selection bias introduced by neuropsychological assessments. *Canadian Journal of Neurological Sciences* 2010;37:264-8. FA & SA (IF 2.006; Citations 19)

119. **Olson R**, Chhanabhai T, McKenzie M. Feasibility study of the Montreal cognitive assessment (MoCA) in patients with brain metastases. *Support Care Cancer* 2008;16:1273-8. FA & SA (IF 2.698; Citations 158)
120. Hausner G, **Olson R**, Johnson I, Simon D, Sanders E, Karol K, McCourt R, and Zimmerly S. Origin and evolution of *trnK (matK)* intron: A model for evolution of group II intron RNA structures. *Molecular Biology and Evolution* 2006;23(2):380-91. CA. *This was basic science work that I was primarily responsible for as a honours student during my undergraduate degree.* (IF 14.797; Citations 109)
121. Dai L, Toor N, **Olson R**, Keeping A, Zimmerly S. Database for mobile group II introns. *Nucleic Acids Research* 2003;31(1):424-6. CA [highlighted in the NetWatch section of **Science** 2004;303:1115.] *I worked on this basic science during my undergraduate degree.* (IF 11.561; Citations 133)

(b) *Letters to the Editor & Response to Letters to the Editors*

1. Phillips I, **Olson R**, Palma D, Harrow S. In Response to: 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy?' by Ostler et al. and 'Should We be Offering our Patients with Oligometastases Stereotactic Ablative Body Radiotherapy e No' by Macbeth and Hughes-Davies
2. Jiang W, **Olson R**. Transoral surgery may be less cost effective than radiotherapy. In response to: Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis. *Oral Oncology* 2021;117:105178
3. **Olson R**. In Reply to Raince and Bloom: Has the American Radiation Oncology Community Missed the Opportunity to Test Stereotactic Ablative Radiotherapy for Bone Metastases? *Int J Radiat Oncol Biol Phys* 2015;91(2): 452. (IF 6.203)
4. **Olson R**. Letter to the editor: Study methodology limitations prevent drawing conclusions on low-level laser therapy to prevent oral mucositis for head and neck cancer patients receiving concurrent chemoradiotherapy. *Int J Radiat Oncol Biol Phys*, 2013;85(4):895. (IF 6.203)
5. Le D, **Olson R**. Letter to the editor: Is one-on-one patient navigation cost-effective and necessary? *CMAJ*. Epub Oct 24, 2011. (IF 6.8)
6. **Olson R**. Letter to the Editor: Selection bias potentially overestimates risk of breast pain from radiotherapy. *Radiotherapy & Oncology*, 2011;99(1):99. (IF 5.252)

(c) *Published Conference Abstracts*

1. Baker S, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Mattews Q, Tyldesley S, **Olson R**. Validation of the prognostic utility of ESTRO/EORTC oligometastatic disease classification: a secondary analysis from the population-based phase II SABR-5 trial. Oral Presentation at the American Society of Radiation Oncology (ASTRO) Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3);S31-2.
2. Baker S, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Mattews Q, Tyldesley S, **Olson R**. Predictors of early polymetastatic relapse following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis of the phase II SABR-5 trial. Oral Presentation at the ASTRO Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3);S32.
3. Jiang W, Baker S, Liu M, Bergman A, Mou B, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chan E, Mohamed I, Berrang T, Bang A, Chng N, Mattews Q, Pai H, Lefresne S, Tyldesley S, **Olson R**. Population-based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR): Overall Survival Results of the SABR-5 Trial. Oral Presentation at the ASTRO Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3);S147-8.
4. Sit D, Shookoohi A, Raycraft T, Vu M, Chan M, Chau N, Berthelet E, Tran E, Wu J, **Olson R**, Hamilton S. Locally Advanced, pT4 Well-Differentiated Thyroid Cancer in Young Patients– A Population-based Study. Poster presentation at the ASTRO Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3);e328.
5. **Olson R**, Lapointe V, Benny A, Chan M, Lefresne S, Mckenzie M. Evaluation of Patient Reported Outcome Differences by Radiotherapy Technique for Bone Metastases in a non-Incentivized Health Care System. Poster presentation at the ASTRO Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3);e453

6. D'Angelo A, Arbour G, Koulis T, Hamm J, Speers C, Tyldesley S, Lohrisch C, Nichol A, Yurkowski E, Matlock S, **Olson R**. Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial. . Poster presentation at the ASTRO Annual Conference, Oct, 2022. *Int J Radiat Oncol Biol Phys* 2022;114(S3):e475
7. Yan L, Nichol A, **Olson R**. Validation of the BC-Brain Patient Reported Outcome Questionnaire for Patients iwth Central Nervous System Tumours Treated with Radiotherapy. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 22.
8. Baker S, Jiang W, Mou B, Lund C, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Chng N, Matthews Q, Arbour G, Benny A, Tyldesley S, **Olson R**. Progression Free Survival and Local Control Following Stereotactic Ablative Radiotherapy for up to Five Oligometastases: An Anlysis from the Population-Based Phase II SABR-5 Trial. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 36.
9. Sit D, Chen KT, Zhao B, Chan M, Tran E, Berthelet E, **Olson R**, Hamilton S, Ng T, Chau N, Wu J. Malignant Salivary Gland Tumours and Long-Term Patient Outcomes Based on the American Joint Committee on Cancer 8th Edition Staging System. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 38.
10. Lapointe V, Benny A, Chan M, Lefresne S, Mckenzie M, **Olson R**. Evaluation of Patient Reported Outcome Differences by Radiotherapy Technique for Bone Metastases in a non-Incentivized Health Care System. Oral Presentation in the Plenary Session at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 55.
11. Baker S, Mou B, Jiang W, Liu M, Bergman A, Schellenberg D, Alexander A, Carolan H, Atrchian S, Berrang T, Bang A, Chng N, Matthews Q, Tyldesley S, **Olson R**. Predictors of early polymetastatic relapse following stereotactic ablative radiotherapy for up to 5 oligometastases: a secondary analysis of the phase II SABR-5 trial. Poster Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 65.
12. Sit D, Shookoohi A, Raycraft T, Vu M, Chan M, Chau N, Berthelet E, Tran E, Wu J, **Olson R**, Hamilton S. Outcomes of Locally Advanced, pT4 Well-Differentiated Thyroid Cancer with Overall Survival Stage I Disease – A Population-based Study. Poster Presentation in the Plenary Session at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 81.
13. Tran E, Lam S, Hamilton S, Wu J, Berthelet E, Chan M, Sibug S, Willinsky P, Lapointe V, Hamm J, **Olson R**. Patient Reported Outcomes During Head and Neck Cancer Radiotherapy Using the MD Anderson Symptom Inventory – Head and Neck Module (MDASI-HN). Poster Presentation in the Plenary Session at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 87.
14. D'Angelo A, Arbour G, Koulis T, Hamm J, Speers C, Tyldesley S, Lohrisch C, Nichol A, Yurkowski E, Matlock S, **Olson R**. Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial. Poster Presentation in the Plenary Session at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 28 – Oct 1, 2022. *Radiotherapy and Oncology* 174 (supplement 1): abstract 171.
15. **Olson R**, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexandar A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Mestrovic A, Hyde D, Huang V, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to Five Oligometastases: Preliminary Results of the SABR-5 Trial. Oral Presentation in the Clinical Trials and Innovation Session at the American Society of Annual Conference, Oct 24, 2021. *Int J Radiat Onc Biol Phy* 111 (3S); S4, abstract 6.
16. **Olson R**, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexandar A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Mestrovic A, Hyde D, Huang V, Lund C, Pai H, Valev B, Lefresne S, Tyldesley S. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to Five Oligometastases: Preliminary Results of the SABR-5 Trial. Plenary Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 29 – Oct 1, 2021. *Radiotherapy and Oncology* 163 (supplement 1; 2021): abstract 2.

17. Qu M, Chen Y, Zaric G, Senan S, **Olson R**, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senth S, Swaminath A, Kopek N, Liu M, Warner A, Rodrigues G, Palma D, Louie A. Cost-Effectiveness of SABR in Oligometastatic Cancer: an Economic Analysis based on Long-Term Results of the SABR-COMET Randomized Trial. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 29 – Oct 1, 2021. Radiotherapy and Oncology 163 (supplement 1; 2021): abstract 23.
18. Hamilton S, Berthelet E, Chan M, Tran E, Wu J, **Olson R**. Patient Reported Outcomes and Complications during Head and Neck Cancer Radiotherapy Before versus During the COVID-19 Pandemic. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 29 – Oct 1, 2021. Radiotherapy and Oncology 163 (supplement 1; 2021): abstract 39.
19. Urban R, Wong J, Lim P, Zhang S, Spadinger I, **Olson R**, Bachand F, Ho C, Tinker A, Gondara L, Hamilton S. Cervical Cancer Patient Reported Gastrointestinal Outcomes: Intensity/Volumetric Modulated Versus 3D Conformal Radiation Therapy. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 29 – Oct 1, 2021. Radiotherapy and Oncology 163 (supplement 1; 2021): abstract 44.
20. Medhurst K, Howard F, Koulis T, Dosani M, Dahinten S, Willinsky P, **Olson R**. Patient Reported Outcomes in Breast Cancer: Development and Validation of a Novel and Clinically Useful Questionnaire. Poster Walk Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 29 – Oct 1, 2021. Radiotherapy and Oncology 163 (supplement 1; 2021): abstract 135.
21. Palma D, **Olson R**, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Ahmad B, Schlijper R, Laba JU, Qu M, Schelleberg D, Senth S, Swaminath A, Kopek N, Liu M, oore K, Currie S, Bauman G, Warner A, Senan S. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-term results of the SABR-COMET Randomized Trial. Plenary Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S7
22. Jasper K, Matthews Q, Liu B, **Olson R**. Deformable Registration for Evidence-Based PTV Margins in Lung SABR: Can Modern Techniques Facilitate Reduction in PTV Margins while Maintaining IGTV Coverage? Oral Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S16
23. Chan J, Zubizarreta E, van Eck J, Hanna T, Bourque J-M, Gaudet M, Dennis K, **Olson R**, Colemena C, Abdel-Wahab M, Brundage M, Slotman B, Polo A. Geographic Accessibility to Radiotherapy in Canada for Indigenous Populations: Highlighting the Inequities. Oral Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S18
24. Sit D, Chen K, Zhao B, Speers C, Lohrisch C, **Olson R**, Nichol A, Hsu F. Triple Negative Breast Cancer is Associated with inferior Patient Reported Outcomes following Palliative Radiotherapy for Bone Metastases. Oral Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S25
25. Hamilton S, Urban R, Liu A, Chau N, Berthelet E, Wu J, Tran E, Yin Y, **Olson R**. Population-based comparison for Outcomes by Immunosuppression Status in Patients Undergoing Radiotherapy for Squamous Cell Carcinoma of the Oropharynx. Poster Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S53
26. Urban R, **Olson R**, Wu J, Berthelet E, Tran E, Hamm J, Hamilton S. The Prognostic Impact of Radiotherapy Delays in Oropharynx Carcinoma and the Role of HPV Status. Poster Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S55.
27. O'Donnel J, Barbera L, **Olson R**, Brown E, Bird L, Caissie A, Croke J, Davis C-A, Milosevic M, Brundage M. A Pan-Canadian Approach to Supporting the Collection and Utilization of Patient Reported Outcomes in Radiation Oncology: An Initiative of the Canadian Partnership for Quality Radiotherapy. Poster Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S62
28. Zhan T, Clark H, Thomas S, **Olson R**, Ma R, Schellenberg. Stereotactic Ablative Radiotherapy (SABR) for Oligometastases: Risk Stratification using Positional Uncertainty. Poster Presentation at CARO Annual Conference, Sep 23-26, 2020. Radiotherapy and Oncology 150 (supplement 1; 2020): S85

29. Sit D, Koh W, Shokoohi A, Tran E, Berthelet E, Wu J, **Olson R**, Hamilton S. Treatment and Outcomes in pT4 Well-Differentiated Thyroid Cancer. Oral Presentation at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S24.
30. Urban R, Goday T, **Olson R**, Wu J, Berthelete E, Tran E, DeVries K, Wilson D, Hamilton S. PET Scan Assessment of Response 12 weeks Post Radiotherapy in Oropharynx Head and Neck Cancer: The Impact of p16 Status. Oral Presentation at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S24-5.
31. Oh J, Tran E, Berthelet E, Wu J, **Olson R**, Bowman A, Reynolds C, Liu A, Hamilton S. Nutritional Risk Index in Patients Undergoing Chemoradiation Therapy for Oral Cavity and Oropharynx Cancer. Oral Presentation at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S26
32. **Olson R**, Senan S, Harrow S, Gaede S, Louie a, Haasbeek N, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) versus Standard of Care Palliative Treatments: A Secondary Analysis of the SABR-COMET Randomized Trial. Oral Presentation in the Reviewer's Choice session at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S41.
33. Qu M, Chen U, Zaric G, Senan S, **Olson R**, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senthil S, Swaminath A, Kopek N, Liu M, Warner A, Rodrigues G, Palma D, Louie A. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. Oral Presentation in the Reviewer's Choice session at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S41-2.
34. Berthelet E, Tran E, Zhang S, Hamilton S, Wu J, **Olson R**, Bergman A. The Impact of Advanced Image Registration and 3-D EQD2 Dose Conversion on PTV and CTV Coverage in the Retreatment of Nasopharyngeal Cancer: A Case Study. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S66
35. Grahame S, Facchin E, Morris D, **Olson R**, Koulis T, Duzenli C. A Breast Skin Assessment Pilot (POSI B-SKIP) Comparing Patient Reported Outcomes and Therapist Assessment of Moist Desquamation in Breast Radiotherapy. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S77.
36. Hamilton S, Tran E, Ho C, Wu J, Berthelet E, DeVries K, Lapointe V, Bowman A, Reynolds C, **Olson R**. Patient Reported Outcome Measures in Patients Undergoing Radiotherapy for Head and Neck Cancer. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): 80-1.
37. Brown E, O'Donnell J, Barbera L, Bird L, Caissie A, Davis C-A, Kildea J, Milosevic M, **Olson R**, Brundage M. Patient Reported Outcomes Used in Radiation Programs Across Canada. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S89.
38. Schlijper R, Bos S, Hamilton S, Tran E, Berthelete E, Wu J, **Olson R**. 90-Day Mortality after Radical Radiotherapy for Head and Neck Cancer: A Population-Based Comparison between Rural and Urban Patients. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S89-90.
39. Zhao Y, Yeung R, Beaton L, Liu M, **Olson R**, Schellenberg D. Outcomes of Stereotactic Ablative Radiotherapy for Lymph Node Oligometastases. Poster at the CARO Annual Conference, Oct 2-5, 2019, Halifax, NS. Radiotherapy and Oncology 139 (S1): S95
40. **Olson R**, Senan, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman G, Warner A, Palma D. Quality of Life Outcomes after Stereotactic Ablative Radiotherapy (SABR) vs. Standard of Care Palliative Treatments in the Oligometastatic Setting. Oral Presentation at the American Society of Radiation Oncology (ASTRO) Annual Meeting, Sep 16-19, 2019, Chicago, IL. Int J Radiat Oncol Biol Phys 105 (1):S72-3.
  - a. **This was selected for a press release in the ASCO post**
41. Sit D, Koh W, Shokoohi A, Tran E, Berthelet E, **Olson R**, Hamilton S. Treatment and Outcomes in pT4 well-differentiated thyroid cancer. Poster discussion at the ASTRO annual Meeting Sep 16-19, 2019, Chicago, IL. Int J Radiat Oncol Biol Phys 105 (1):E436.
42. Urban R, Godoy T, **Olson R**, Wu J, Berthelet E, Tran E, DeVries K, Wilson D, Hamilton S. PET Scan Assessment of Response 12 weeks Post Radical Radiotherapy in Oropharynx Head and Neck Cancer: The Impact of p16 Status. Poster discussion at the ASTRO annual Meeting Sep 16-19, 2019, Chicago, IL. Int J Radiat Oncol Biol Phys 105 (1):E429-30.
43. Qu M, Chen Y, Zaric G, **Olson R**, Harrow S, John-Baptiste A, Gaede S, Mulroy L, Schellenberg D, Senthil S, Swaminath A, Kopek N, Liu M, Warner A, Rodrigues G, Palma D, Louie A. Is SABR Cost-

- Effective in Oligometastatic Cancer? An Economic Analysis of SABR-COMET. Oral presentation at the ASTRO annual Meeting Sep 16-19, 2019, Chicago, IL. *Int J Radiat Oncol Biol Phys* 105 (1):S100-1.
44. Zhao Y, Yeung R, Beaton L, Liu M, **Olson R**, Schellenberg D. Outcomes of Stereotactic Ablative Radiotherapy for Lymph Node Oligometastases. Poster discussion at the ASTRO annual Meeting Sep 16-19, 2019, Chicago, IL. *Int J Radiat Oncol Biol Phys* 105 (1):E574-5.
  45. Schlijper R, Bos S, Hamilton S, Tran E, Berthelet E, Wu J, **Olson R**. 90-Day Mortality after Radical Radiotherapy for Head and Neck Cancer: A Population-Based Comparison between Rural and Urban Patients. Poster discussion at the ASTRO annual Meeting Sep 16-19, 2019, Chicago, IL. *Int J Radiat Oncol Biol Phys* 105 (1):E460.
  46. **Olson R**, Liu M, Bergman A, Lam S, Hsu F, Mou B, Berrant T, Mestrovic A, Chng N, Hyde D, Matthews Q, Lund C, Glick D, Pai H, Basran P, Carolan H, Valev B, Tyldesley S, Schellenberg D. Population-based Phase II trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 oligometastases: SABR-5. European Society of Radiation Oncology (ESTRO) Annual Meeting April 2019. *Radiotherapy and Oncology* 133;S871.
  47. Palma D, **Olson R**, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopeck N, Liu M, Moore K, Currie S, Warner A, Senan S. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Plenary presentation at the American Society of Therapeutic Radiation Oncology (ASTRO) Annual Meeting, Oct 21-24, 2018. *Int J Radiat Oncol Biol Phys* 102 (3): S3-4.
  48. Koullis T, Nichol A, Tyldesley S, Truong P, Weir L, Speers C, Lovedeep G, **Olson R**. Cancer-Specific Outcomes of Hypofractionated Locoregional Radiation Therapy for Patients with Stage I-III Breast Cancer. Oral presentation at ASTRO Annual Meeting, Oct 21-24, 2018. *Int J Radiat Oncol Biol Phys* 102 (3): S79.
  49. **Olson R**, Chan M, Minhas N, Kandola G. Prescription of Evidence-Based Single Fraction Radiation Therapy for Bone Metastases Can be Increased in a Meaningful and Sustained Way on a Population Level Using Quality Assurance Data. Oral presentation at ASTRO Annual Meeting, Oct 21-24, 2018. *Int J Radiat Oncol Biol Phys* 102 (3): S166-7
  50. Fraser I, **Olson R**, Regan J, McKenzie M, Lefresne. Radiation Therapy Near End of Life in a Rapid Access Lung Cancer Clinic Compared to Standard Practice. ASTRO Annual Meeting, Oct 21-24, 2018. *Int J Radiat Oncol Biol Phys* 102 (3): S223
  51. Fraser I, Regan J, Lefresne S, **Olson R**. Palliative Radiation Therapy Near the End of Life in Lung Cancer Patients: A Population-Based Analysis. ASTRO Annual Meeting, Oct 21-24, 2018. *Int J Radiat Oncol Biol Phys* 102 (3): e661.
  52. Oh J, Prisman E, **Olson R**, Berthelet E, Wu J, Tran E, Hamilton S. Primary Organ preservation versus total laryngectomy for T4 larynx cancer. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S6 (abstract 10).
  53. Koullis T, **Olson R**, Nichol A, Tyldesley S, Truong P, Speers C, Gondara L, Kolisang L, Almahmudi M. Cancer-specific outcomes of hypofractionated loco-regional radiotherapy for patients with stage I-III breast cancer. Oral Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S6 (abstract 12).
  54. Bale M, **Olson R**, Lapointe V, Minhas N, McLay M, Hsu F. Comparison of patient reported outcomes by EGFR and ALK mutation status in lung cancer patients treated with palliative radiotherapy for bone metastases. Oral Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S10 (abstract 22).
  55. **Olson R**, Chan M, Minhas N, Kandola G. Programmatic comparison and dissemination of single fraction radiotherapy prescribing practices for bone metastases can result in a meaningful and lasting change in practice in a population level. Oral Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S29(abstract 78).
  56. Palma D, **Olson R**, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthil S, Swaminath A, Kopeck N, Liu M, Moore K, Currie S, Warner A, Senan S. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers (SABR-COMET): results of a randomized trial. Oral Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S37(abstract 103).
  57. Hamilton S, Tran E, Lapointe V, Caon J, Bowman A, Reynolds C, Lagman M, Ho C, Brown E, **Olson R**. Patient reported outcomes during radiotherapy for head and neck cancer: A Prospective

- Outcomes and Support Initiative. Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S94 (abstract 277).
58. Fraser I, **Olson R**, Regan J, McKenzie M, Lefresne S. Radiotherapy near end of life in a rapid access lung cancer clinic compared to standard practice. Presentation at the CARO Annual Meeting. Montreal, QC. Sep 12-15, 2018. *Radiat and Oncol* 2018; 129(suppl1);S99 (abstract 291).
  59. Koulis T, Speers C, Hamm J, Dang A, Power J, Nichol A, Tyldesly S, **Olson R**. Radiation therapy prescribing patterns across 6 breast cancer scenarios. Oral Presentation at the CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S2 (abstract 4).
  60. McLay M, **Olson R**, Callaghan R. Assessing the hazard of tobacco-related cancers among individuals with psychiatric disorders in British Columbia. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S9 (abstract 20).
  61. Chan M, **Olson R**, Lefresne S, McKenzie M. Patterns of radiation therapy technology use in the treatment of bone metastases. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S10 (abstract 22).
  62. Koulis T, Matthews Q, Chng N, Engel B, Valev B, **Olson R**. Dosimetric impact of re-planning during a course of curative intent head and neck radiation. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S14 (abstract 33).
  63. Dosani M, **Olson R**, Yang R, Wilson D, Liu M, Yong-Hing CJ, Hamm J, Lund C, Schellenberg D. Metabolic tumour volume is prognostic of outcomes in patients with non-small cell lung cancer treated with stereotactic ablative radiotherapy. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S19 (abstract 45).
  64. Chan M, Lapointe V, **Olson R**, Holloway C, Bachand F, Lim P, Parsons C. Validation of patient reported outcome measures in patients receiving high dose pelvic radiation therapy for gynecologic malignancies. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S29 (abstract 70).
  65. Hamilton S, Tran E, Berthelet E, Wu J, **Olson R**. Early (90-day) mortality after radical radiotherapy for head and neck squamous cell carcinoma: A population-based analysis. Oral presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S32 (abstract 76).
  66. Chaudry A, Koulis T, Speers C, **Olson R**. Prescribing practices of endocrine therapy for ductal carcinoma in situ in British Columbia. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S66 (abstract 163).
  67. Yang L, Manhas D, Howard F, **Olson R**. Patient-reported outcome use in oncology: A systematic review of the impact on patient-provider communication. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S68 (abstract 170).
  68. **Olson R**, Lapointe V, Sample S, Ozier D, Rennie H, Mackenzie G, Howard F, Brown E, Nichol A. Feasibility and impact of electronic collection of repeat patient reported anxiety, depression, and suicidal ideation in patients with central nervous system tumours. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S69 (abstract 171).
  69. Thomson C, **Olson R**, Brown E, Lapointe V. The feasibility of creating a clinically useful patient reported lung questionnaire for a provincial radiotherapy program. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S72 (abstract 177).
  70. Manhas D, Yang L, Howard F, **Olson R**. Collecting patient reported outcome measures (PROs) and providing follow-up to palliative cancer patients through the Prospective Outcomes and Support Initiative (POSI): Oncology nurses perspectives of the utility and effect on patient care. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S80 (abstract 200).
  71. McLay M, **Olson R**, Callagahn R. Assessing tobacco-related cancer survival among individuals with psychiatric disorders in British Columbia. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S83 (abstract 211).
  72. Dang A, **Olson R**, Horvat D, Klassen-Ross. Assessing potential improvement in post radiation therapy completion notes from a family physician perspective. Poster presentation at CARO Annual Meeting. Toronto, ON. Sep 14-17, 2017. *Radiat and Oncol* 2017;124(suppl 1); S85 (abstract 214).
  73. **Olson R**, Holloway C, Parsons C, Lim P, Lapointe V, Lomas S, Bowering G, Bachand F. Feasibility of collecting patient reported outcomes for patients receiving curative intent RT for gynecological malignancies. Oral Presentation at the Canadian Association of Radiation Oncology (CARO) Annual Meeting. Banff Alberta, Sep 14-17, 2016. *Radiat and Oncol* 2016 120(suppl 1); S6 (abstract 15).

74. Mclay M, Stedford A, Yurkowski E, Matlock S, Olson R. Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients. Oral presentation at CARO Annual Meeting. Banff Alberta, Sep 14-17, 2016. Radiat and Oncol 2016 120(suppl 1); S7 (abstract 19).
75. Tiwana M, Hughson L, Lehal S, Morton T, Clifford B, Blewett C, Olson R. Cancer incidence and treatment disparities: A perspective from model island communities of Haida Gwaii in British Columbia comparing First Nations and general population. CARO Annual Meeting. Banff Alberta, Sep 14-17, 2016. Radiat and Oncol 2016 120(suppl 1); S30 (abstract 95).
76. Olson R, Maas B, Gondora L, Woods R, Truong P, Olivotto I, Tyldesley S, Nichol A, Weir L. Impact of internal mammary node radiation on survival in patients with breast cancer: Extended follow-up of a population-based analysis. CARO Annual Meeting. Banff Alberta, Sep 14-17, 2016. Radiat and Oncol 2016 120(suppl 1); S44 (abstract 118).
77. Beaton L, Ma R, Hsu R, Gondora L, Carolan H, Olson R, Schellenberg D, Germain F, Cheung A, McKenzie M, Nichol A. The impact of a central nervous system event on cognitive function after radiation treatment in patients with one-ten brain metastases. CARO Annual Meeting. Banff Alberta, Sep 14-17, 2016. Radiat and Oncol 2016 120(suppl 1); S46 (abstract 122).
78. Olson R, Howard F, Lapointe V, Schellenberg D, Nichol A, Ozier D, Bowering G, Curtis S, Walter A, Brown S, Thompson C, Bergin J, Lomas S, Halperin R, Tyldesley S, Beckham W. Feasibility and utility of patient reported outcome collection on a population scale. CARO Annual Meeting. Banff Alberta, Sep 14-17, 2016. Radiat and Oncol 2016 120(suppl 1); S54 (abstract 172).
79. Chan M, Olson R, Lefresne S, McKenzie M. Patterns of radiation technology use in the treatment of bone metastases. ASCO 2016 Palliative Care in Oncology Symposium. J Clin Oncol 34 (suppl 26S; abstr 211).
80. Olson R, Ozier D, LaPointe V, Walter A, Bowering G, Curtis S, Nichol A. Incidence of Patient-Reported Depression at Time of Radiation Therapy Planning for Brain Metastases: Impact of Radiation Therapists and Counseling Services. American Society of Therapeutic Radiation Oncology (ASTRO) 57th Annual Meeting, Oct 18 - 21, 2015. Int J Radiat Oncol Biol Phys 93 (3) E471-2.
81. Conway J, Yurkowski E, Glazier J, Gentles Q, Olson R. Comparison of Patient-Reported Outcomes with Single versus Multiple Fraction Palliative Radiation Therapy for Complicated Bone Metastases. Oral Presentation at ASTRO 57th Annual Meeting, Oct 18 - 21, 2015. Int J Radiat Oncol Biol Phys 93 (3) S62.
82. Barnes M, Tiwana M, Kiraly A, Hutchison M, Olson R. Frequency of Distal Bone Metastases in Patients Treated for Palliative Radiation Therapy and Association with Primary Tumor Types. ASTRO 57th Annual Meeting, Oct 18 - 21, 2015. Int J Radiat Oncol Biol Phys 93 (3) E470.
83. Tiwana M, Barnes M, Yurkowski E, Roden K, Olson R. Incidence and Treatment Patterns for Complicated Bone Metastases in a Population-Based Radiation Therapy Program. ASTRO 57th Annual Meeting, Oct 18 - 21, 2015. Int J Radiat Oncol Biol Phys 93 (3) E471.
84. Olson R, Power J, Glazier J, Mathews L, Tiwana M. Assessment of Patient-Reported Outcome Questions in Breast Cancer Patients Five Years after Adjuvant Breast Radiotherapy. Oral presentation at Canadian Association of Radiation Oncology (CARO) Annual Meeting. Radiat and Oncol 2015;116 S28 (abstract 78).
85. Giambattista J, Lefresne S, Olson R, Carolan H, Loewen S. A Mixed Method Survey on the Impact of a Difficult Canadian Job Market on Radiation Oncology Residents and Program Directors. Short oral presentation at CARO Annual Meeting. Radiat and Oncol 2015:116 S45 (abstract 123).
86. Tiwana M, Barnes M, Yurkowski E, Roden K, Olson R. Incidence and Treatment Patterns of Complicated Bone Metastases in a Population-Based Radiotherapy Program. Poster presentation at CARO Annual Meeting. Radiat and Oncol 2015:116 S69-70 (abstract 192).
87. Olson R, Ozier D, LaPointe V, Walter A, Bowering G, Curtis S, Nichol A. Prevalance of Patient-Reported Depression at time of Radiotherapy Planning for Brain Metastases: Impact on Radiation Therapist and Counselling Services. Poster presentation at CARO Annual Meeting. Radiat and Oncol 2015:116 S70 (abstract 194)
88. Barnes M, Tiwana M, Kiraly A, Olson R. Frequency of Distal Bone Metastases in Patients Treated for Palliative Radiotherapy and Associations with Primary Tumour Types. Poster presentation at CARO Annual Meeting. Radiat and Oncol 2015:116 S71 (abstract 196).
89. Conway J, Glazier J, Yurkowski E, Gentles Q, Olson R. Comparison of Patient-Reported Outcomes with Single versus Multiple Fraction Palliative Radiotherapy for Complicated Bone Metastases. Poster presentation at CARO Annual Meeting. Radiat and Oncol 2015:116 S71 (abstract 197).
90. Olson R, Daudt H, Stephen J, French J, Halperin R, Bahl G, Beckham W, Olivotto I. Feasibility of Population-Based Collection of Patient-Reported Outcomes Measures in a Provincial Radiation



- Therapy Program. ASTRO 56th Annual Meeting, Sep 14 - 17, 2014. *Int J Radiat Oncol Biol Phys* 2014;90(1);S718-9.
91. Conway J, Olivotto I, Miller S, Halperin R, Hoegler D, Beckahm W, Stephen J, Daudt H, French J, **Olson R**. Patient reported outcomes on the impact of single versus multiple fraction palliative radiotherapy for uncomplicated bone metastases on pain, function, and degree of symptom distress. Oral presentation at ASTRO 56th Annual Meeting, Sep 14 - 17, 2014. *Int J Radiat Oncol Biol Phys* 2014;90(1);S80. *One of 18 abstracts selected for an ASTRO press release: <https://www.astro.org/News-and-Media/News-Releases/2014/Patient-reported-data-indicates-that-single-fraction-RT-is-as-effective-as-multiple-fraction-RT-for-patients-with-bone-metastases.aspx>*
  92. Hamilton S, Tyldesley S, Li D, **Olson R**, McBride M. Second malignancies after adjuvant radiotherapy for early stage breast cancer: is there an increased risk with the addition of regional radiotherapy. Oral presentation at ASTRO 56th Annual Meeting, Sep 14 - 17, 2014. *Int J Radiat Oncol Biol Phys* 2014;90(1);S47.
  93. Lefresne S, Levy K, Cashman R, Santibanez P, Tyldesley S, **Olson R**. A Multidisciplinary rapid access clinic – providing more than just rapid access. Oral presentation at ASTRO 56th Annual Meeting, Sep 14 - 17, 2014. *Int J Radiat Oncol Biol Phys* 2014;90(1);S568.
  94. Barnes M, Tiwana M, Miller S, Kiraly A, Olivotto I, **Olson R**. Radiation Therapy Fractionation Schedules Prescribed Are Dependent on the Distance a Patient Travels to Receive Treatment. American Society of Therapeutic Radiation Oncology (ASTRO) 56th Annual Meeting, Sep 14 - 17, 2014. *Int J Radiat Oncol Biol Phys* 2014;90(1);S692.
  95. Conway J, Olivotto I, Miller S, Halperin R, Hoegler D, Beckham W, Stephen J, Daudt H, French J, **Olson R**. Patient reported outcomes on the impact of single versus multiple fraction palliative radiotherapy for uncomplicated bone metastases on pain, function, and degree of symptom distress. Oral poster discussion at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S10-11 (abstract 27).
  96. **Olson R**, Daudt H, Stephen J, French J, Halperin R, Bahl G, Beckham W, Olivotto I. Feasibility of population based collection of patient reported outcome measures in a provincial radiotherapy program. Oral poster discussion at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S1 (abstract 28).
  97. **Olson R**, Olivotto I, Tiwana M, Barnes M, Halperin R, Miller S, Hoegler D, French J. Impact of program-wide dissemination of the inconsistent utilization of single fraction radiotherapy for bone metastases across a provincial program. Oral presentation at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S15 (abstract 39).
  98. Olivotto I, Soo J, **Olson R**, Rowe L, Clendenning B-S, Pastuch A, Jensen B, French J, Halperin R. Patient-centred cancer service design: What do patients prefer regarding time of day, day of week and travel duration to receive radiation therapy (RT)? Oral presentation at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S15 (abstract 40).
  99. Hamilton S, Tyldesley S, Dongdong L, **Olson R**, McBride M. Second malignancies after adjuvant radiotherapy for early stage breast cancer: Is there an increased risk with the addition of regional radiotherapy? Oral presentation at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S22 (abstract 58)
  100. Beecham K, Tyldesley S, Speers C, Simmons C, Cheifitz R, Sutter M, Voduc D, **Olson R**. Neoadjuvant systemic therapy utilization in breast cancer: Potential impact on nodal radiotherapy. Oral presentation at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S31 (abstract 83).
  101. Nichol A, McKenzie M, Ma R, Hsu F, Cheung A, Gondara L, Peacock M, Carolan H, **Olson R**, Germain F, Schellenberg D, Vellani R. A phase II study of whole brain radiotherapy (WBRT) with simultaneous integrated boost (SIB) using volumetric modulated arc therapy for one to ten brain metastases. Oral presentation at CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S36 (abstract 95).
  102. Peacock M, McKenzie M, Ma R, Hsu F, Cheung A, Carolan A, **Olson R**, Germain F, Schellenberg D, Nichol A. Defining thresholds for volumetric response as a compared to response evaluation criteria in solid tumours (RECIST) after radiotherapy for brain metastases. CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S42 (abstract 111).
  103. Singh T, Barnes M, Kiraly M, Miller S, Hoegler D, Olivotto I, **Olson R**. Palliative radiotherapy for bone metastases: Population-based utilization near end of life in a Canadian province. CARO Annual Meeting, Aug 25 – 28, 2014. *Radiat and Oncol* 2014;112 S6 (abstract 177).

104. Barnes M, Tiwana M, Miller S, Olivotto I, Kiraly A, **Olson R**. Radiotherapy fractionation schedules prescribed are dependent on the distance a patient travels to receive treatment. CARO Annual Meeting, Aug 25 – 28, 2014. Radiat and Oncol 2014;112 S67(abstract 178).
105. Lefresne S, Olson R, Cashman R, Jiang W, Kostuik P, Levy K, Liu M, Carolan H, McKenzie M, Berthelet E. Prospective analysis of patient reported symptoms and quality of life in patients with incurable lung cancer treated in a rapid access clinic. CARO Annual Meeting, Aug 25 – 28, 2014. Radiat and Oncol 2014;112 S67-8 (abstract 180).
106. **Olson R, Tiwana M, Barnes M**, Miller S, Hoegler D. Use of single fraction palliative radiation therapy for bone metastases: population-based practice patterns in British Columbia over a 5-year period. Oral presentation at the ASTRO 55th Annual Meeting, Sep 22 - 24, 2013. Int J Radiat Oncol Biol Phys 2013; 87 (3) S88-9 (abstract 215). Subsequently selected and presented at the 1st Best of ASTRO meeting, Nov 8-9, 2013. FA & SA
107. Tiwana M, Wu J, Hay J, Wong F, and **Olson R**. Head-and-neck cancers as a second primary following an index head-and-neck cancer: population-based outcomes over a 25-year period. ASTRO 55th Annual Meeting, Sep 22 - 24, 2013. Int J Radiat Oncol Biol Phys 2013; 87 (3) S481-2 (abstract 2731). SA
108. Lefresne S, Levy K, Cashman R, Santibanez P, Tyldesly S, and Olson R. A multidisciplinary rapid access clinic: more than just rapid access. ASTRO 55th Annual Meeting, Sep 22 - 24, 2013. Int J Radiat Oncol Biol Phys 2013; 87 (3) S568 (abstract 2959). SA
109. **Olson R**, Turnbull K, Munroe D, Tobin P, Ward A. Prospective evaluation of unmet needs of rural cancer survivors: Comparison between rural aboriginal and non-aboriginal communities. ASTRO 55th Annual Meeting, Sep 22 - 24, 2013. Int J Radiat Oncol Biol Phys 2013; 87 (3) S568 (abstract 2974). FA & SA
110. **Olson R**, Munroe D, Turnbull K, Ward A, Tobin P. Prospective evaluation of unmet needs of rural cancer survivors: Comparison between four First Nations and four non-First Nation communities. Oral presentation at the Canadian Association of Radiation Oncology (CARO) Annual Meeting, Sep 18 - 22, 2013 Radiotherapy & Oncology 108 (Suppl. 1): S9 (abstract 22). FA & SA
111. Ye A, Cheung W, Goodard K, Olson R. Pattern of follow-up in oncologic care across Canada. CARO Annual Meeting, Sep 18 - 22, 2013. Radiotherapy & Oncology 108 (Suppl. 1): S67 (abstract 176). SA
112. Lefresne S, Cheung W, Hay J, Speers C, Olson R. Population based exploration of radiotherapy utilization in rural, small, and urban local health authorities. CARO Annual Meeting, Sep 18 - 22, 2013. Radiotherapy & Oncology 108 (Suppl. 1): S90 (abstract 239). SA
113. **Olson R, Tiwana M, Barnes M**, Miller S, Hoegler D. Use of single fraction palliative radiotherapy for bone metastases: Population based practice patterns over a five year period. FA & SA
114. **Olson R**, Munroe D, Turnbull K, Ward A, Tobin P. Prospective evaluation of unmet needs of rural cancer survivors: Comparison between four First Nations and four non-First Nation communities. CARO Annual Meeting, Sep 18 - 22, 2013. Radiotherapy & Oncology 108 (Suppl. 1): S90-1 (abstract 241). FA & SA
115. **Olson R**, Munroe D, Turnbull K, Ward A, Tobin P. Prospective evaluation of unmet needs of rural cancer survivors: Comparison between four First Nations and four non-First Nation communities. American Psychosocial Oncology 10<sup>th</sup> Annual Conference Feb 13 – 17, 2013. Psycho-Oncology 22 (Suppl. 2): 28 (abstract 13-1). FA & SA
116. Lo A, Liu M, Chan E, Lund C, Loewen S, Cao J, Schellenberg D, Carolan H, Berrang T, Olson R. A province wide quality assurance (QA) review of stereotactic body radiotherapy (SBRT) treatment planning for lung cancer. ASTRO Annual Meeting. Oct 28 – 31, 2012. Int J Radiat Oncol Biol Phys; 84(3) S132. SA
117. **Olson R**, Wong F, Wu J, Hay J. Twenty-five-year Survival Outcomes for Squamous Cell Carcinomas of the Head and Neck: Population-based Outcomes from a Canadian Province. ASTRO Annual Meeting. Boston, MA. Oct 28 – 31, 2012. Int J Radiat Oncol Biol Phys 2012; 84(3) S204. FA & SA
118. Karam I, Wilson G, Bowman A, Wong F, Olson R. Retrospective Comparison of 2 Feeding Tube Approaches for Head-and-Neck Cancer Patients Receiving Concurrent Chemoradiation Therapy. ASTRO Annual Meeting. Oct 28 – 31, 2012. Int J Radiat Oncol Biol Phys; 84(3) S516. SA
119. Lo A, Liu M, Chan E, Lund C, Loewen S, Cao J, Schellenberg D, Carolan H, Berrang T, Olson R. A province wide quality assurance (QA) review of stereotactic body radiotherapy (SBRT) treatment planning for lung cancer. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S25 (abstract 64). SA

120. Goddard K, **Olson R**, Parkinson M, Nurcombe W, Bobinski MA, Howard F. Life challenges experienced by long term pediatric brain tumour survivors: parents' perspectives. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S25 (abstract 65). CA
121. Lucas S, Linden W, **Olson R**. Prognostic utility of anxiety and depression levels at time of diagnosis in stage III lung cancer. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S27 (abstract 70). SA
122. **Olson R**, Parkinson M, Cashman R, McKenzie M, Yao J, Mackenzie G, Stephen J. Changes in quality of life, functional status, and cognitive function from baseline to 6 months post treatment in patients with high grade gliomas. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S28 (abstract 71). FA & SA
123. Cao J, Olivotto I, Truong P, **Olson R**, Keyes M, Weir L, Gelmon K, Bernstein V, Woods R, Speers C, Tyldesley S. Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15 year outcomes of a population based cohort. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S32 (abstract 83) CA
124. **Olson R**, Wong F, Wu J, Hay J. Twenty-five year survival outcomes for squamous cell carcinomas of the head and neck: Population based outcomes from a Canadian province. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S43 (abstract 108). FA & SA
125. Cao J, Schellenberg D, Mohamad I, Lund C, Louie A, Palma D, Rodrigues G, **Olson R**, Tyldesley S. Estimating the need for stereotactic ablative radiotherapy (SABR) for lung cancer: an evidence based epidemiological approach. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S60 (abstract 154). CA
126. Tran E, Carolan H, **Olson R**. Radiation Oncology resident workload in a Canadian province: Analysis of new patients and follow up dictation data. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S64 (abstract 163). CA
127. Goddard K, **Olson R**, Hung G, Howard F. Childhood cancer survivors' perspectives and preferences for long-term follow up. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S66 (abstract 169). CA
128. Lefresne S, Levy K, Cashman R, **Olson R**. Pilot interdisciplinary palliative lung rapid access radiotherapy clinic – experiences, perceptions, and goals. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S75 (abstract 191). SA
129. **Olson R**, Lengoc S, French J, McGahan, Tyldesley S, Soo J. Relationships between family physicians' tested knowledge, self-perceived knowledge, and utilization of palliative radiotherapy. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S76 (abstract 192). FA & SA
130. Cao J, Tyldesley S, Carolan H, Woods R, Speers C, **Olson R**. Choroidal metastases in breast cancer: outcomes of a population based cohort. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S80 (abstract 203). SA
131. Karam I, Wilson G, Bowman A, Wong F, **Olson R**. Retrospective comparison of two feeding tube approaches for head & neck cancer patients received concurrent chemoradiotherapy treatment. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S87 (abstract 221). SA
132. Le D, Wozney H, **Olson R**. Breast cancer care navigation in rural settings: feasibility study of a systems-level approach. CARO Annual Meeting. Sep 12 – 15, 2012. Radiother Oncol 2012;104(suppl 2);S88 (abstract 224). SA
133. Lengoc S, Soo J, McGahan C, French J, Tyldesley S, **Olson R**. Referral patterns of patients for palliative radiation therapy in British Columbia: A comparison between northern and urban physicians. 53<sup>rd</sup> Annual American Society of Radiation Oncology (ASTRO) Meeting. Miami, Florida, October 2 – 6, 2011. Int J Radiat Onc Biol Phys 2011; 81(2 supplement) S567-8. SA
134. Caon J, **Olson R**, Tyldesley S, Bergman A, Bobinski MA, Fong M, Vellani R, Khan M, Goddard M. National survey of health care providers' views on the risk of inadvertent exposure of pregnant patients to ionizing radiation in Canadian radiotherapy department. 53<sup>rd</sup> Annual ASTRO Meeting. Miami, Florida, October 2 – 6, 2011. Int J Radiat Onc Biol Phys 2011; 81(2 supplement) S567. CA
135. Lefresne S and **Olson R**. Retrospective Exploration of the Impact of Quality Assurance Rounds in a Canadian Radiotherapy Department. 53<sup>rd</sup> Annual ASTRO Meeting. Miami, Florida, October 2 – 6, 2011. Int J Radiat Onc Biol Phys 2011; 81(2 supplement) S562. SA
136. **Olson R**, Woods R, Lau J, Speers C, Lo A, Tyldesley S, Weir L. Impact of internal mammary node inclusion in the radiation treatment volume on the outcomes of breast cancer patients treated with loco-regional radiation after 6 years of follow-up. Canadian Association of Radiation Oncology

- (CARO) Meeting 2011, Winnipeg, Sep 14 -17, 2011. Radiother Oncol 2011;100 (Suppl1):S30-1 (abst78). FA & SA
137. **Olson R**, Brastianos P, Palma D. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: A systematic review and meta-analysis. Oral presentation at CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S14 (abst37). FA & SA
  138. **Olson R**, Caron N, Olivotto I, Speers C, Chia S, Davidson A, Coldman A, Nichol A, Bajdik C, Tyldesley S. Population based comparison of breast cancer screening and treatment utilization by remoteness of residence in a Canadian province. CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S77 (abst208). FA & SA
  139. Lengoc S, Soo J, McGahan C, French J, Tyldesley S, **Olson R**. Referral patterns of patients for palliative radiation therapy in British Columbia: A comparison between northern and urban physicians. CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S78 (abst211). SA
  140. Lund C, Liu M, Wu J, Carolan H, **Olson R**, Schellenberg D. The Current use of stereotactic body radiotherapy for lung tumours across Canada. Oral presentation at CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S25 (abst64). SA
  141. **Caon J**, **Olson R**, Tyldesley S, Bergman A, Bobinski MA, Fong M, Vellani R, Khan M, Goddard M. National survey of health care providers' views on the risk of inadvertent exposure of pregnant patients to ionizing radiation in Canadian radiotherapy department. Oral presentation at CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S26 (abst66). CA
  142. **Lefresne S** and **Olson R**. Retrospective exploration of the impact of radiotherapy quality assurance rounds. CARO Meeting 2011, Winnipeg, Sep 14 – 17, 2011. Radiother Oncol 2011;100 (Suppl1):S75 (abst203). SA
  143. **Olson R**, Woods R, Lau J, Speers C, Lo A, Tyldesley S, Weir L. Impact of internal mammary node inclusion in the radiation treatment volume on the outcomes of breast cancer patients treated with loco-regional radiation after six years of follow-up. Oral presentation at the 2011 ASCO Breast Cancer Symposium, San Francisco, Sep 8 – 10, 2011. J Clin Oncol 29, 2011 (suppl 27; abstr 81). FA & SA
  144. **Olson R**, Caron N, Olivotto I, Speers C, Chia S, Davidson A, Coldman A, Nichol A, Bajdik C, Tyldesley S. Population based comparison of breast cancer screening and treatment utilization by remoteness of residence in British Columbia. 2011 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, USA. Jun 3 – 7, 2011. J Clin Oncol 29: 2011 (suppl; abstr 593). FA & SA
  145. **Olson R**, Carolan H, Parkinson M, Chhanabhai, McKenzie M. Prospective comparison of the prognostic utility of the Montreal cognitive assessment and the Mini Mental State Examination in patients with brain metastases. 52<sup>nd</sup> Annual ASTRO Meeting. San Diego, USA. Oct 31 – Nov 4, 2010. Int J Radiat Oncol Biol Phys. 2010;78(3 Supplement):S264. FA & SA
  146. **Olson R**, Hukin J, Steenburgh S, Rassekh R, Ho A, Bobinski M, Goddard K. Health care providers' views of informed consent and joint decision making in pediatric patients with brain tumours. 42<sup>nd</sup> Congress of the International Society of Pediatric Oncology (SIOP). Boston, USA. October 21-24, 2010. Pediatric Blood and Cancer 2010;55(5):918-9. Abstract PM018. FA
  147. Goddard K, Brown T, Dezorci P, Hukin J, Johnston D, Punnett A, Rassekh S, **Olson R**. Case-based interactive e-learning programs for pediatric oncology: rationale, development and user evaluation results. 42<sup>nd</sup> Congress of the International Society of Pediatric Oncology (SIOP). Boston, USA. October 21-24, 2010. Pediatric Blood and Cancer 2010;55(5):974. Abstract PT012. SA
  148. **Olson R**, **Hung G**, Bobinski M, Goddard K. Impact of legal problems on quality of life in adult survivors of pediatric malignancies. CARO 2010 Meeting, Vancouver, Sept 22 – 25, 2010. Radiother Oncol 2010;96 (Suppl2):S64-5 (abst199). FA & SA
  149. **Olson R**, Carolan M, Parkinson M, Chhanabhai T, McKenzie M. Prospective evaluation of the prognostic utility of the Mini Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) in patients with brain metastases. Oral presentation at CARO 2010 Meeting, Vancouver, Sept 22 – 25, 2010. Radiother Oncol 2010;96 (Suppl2):S15 (abst45). FA & SA
  150. **Olson R**, Hukin J, Steenburgh S, Rassekh R, Ho A, Bobinski M, Goddard K. Pediatric radiation oncologists' views of informed consent and joint decision making. CARO 2010 Meeting, Vancouver, Sept 22 – 25, 2010. Radiother Oncol 2010;96 (Suppl2):S38 (abst116). FA
  151. Tyldesley S, **Olson R**, Nichol A, Speers C, Chia S, Badjic C, Coldman A. Population based stage, treatment and outcomes for patients with breast cancer in a Canadian province. CARO 2010 Meeting, Vancouver, Sept 22 – 25, 2010. Radiother Oncol 2010;96 (Suppl2):S31 (abst93). CA

152. **Olson R**, Hung G, Bobinski M, Goddard K. Prospective evaluation of legal needs in adult survivors of pediatric malignancies. MASCC/ISOO 2010 International Symposium. Vancouver, BC, Canada. June 24 – 26, 2010. Support Care Cancer 2010;18 (suppl3). FA
153. **Olson R**, Hung G, Bobinski M, Goddard K. Comparison of legal needs in adult survivors of paediatric central nervous system (CNS) and non-CNS malignancies. Oral presentation at the 14<sup>th</sup> International Symposium on Pediatric Neuro-Oncology (ISPNO). Vienna, Austria. June 20 -23, 2010. J Neuro-Oncology 2010;12(6):ii30. FA
154. **Olson R**, Ma V, Hukin J, Johnston D, Singhal A, Goddard K. A Case-based interactive e-learning program for pediatric neuro-oncology: Rationale, development and user evaluation results. 14<sup>th</sup> ISPNO. Vienna, Austria. June 20-23, 2010. Journal of Neuro-Oncology 2010;12(6):ii56. FA
155. **Olson R**, Hung G, Bobinski M, Goddard K. Comparison of legal needs in adult survivors of pediatric central nervous system (CNS) versus non-CNS malignancies. 14<sup>th</sup> Biennial Canadian Neuro-Oncology (CNO) Meeting. Niagara-on-the-Lake, Ontario, Canada. May 14 – 16, 2010. Canadian Journal of Neurological Sciences 2010;37(suppl.1). FA
156. **Olson R**, Ma V, Hukin J, Johnston D, Singhal A, Goddard K. A case-based interactive e-learning program for pediatric neuro-oncology: rationale, development and user evaluation results. 14<sup>th</sup> Biennial CNO Meeting. Niagara-on-the-Lake, Ontario, Canada. May 14 – 16, 2010. Canadian Journal of Neurological Sciences 2010;37(suppl.1). FA
157. **Olson R**, Hukin J, Steenburgh S, Rassekh R, Ho A, Bobinski M, Goddard K. Oncologists' views of informed consent and joint decision making in pediatric oncology. Oral presentation at the American Psychosocial Oncology Society (APOS) 7th Annual Conference. New Orleans, LA. February 18 – 21, 2010. Abstract 12-2. Psycho-Oncology 2010;19(suppl. 1):S23-4. FA
158. **Olson R**, Iverson G, Parkinson M, Carolan H, Ellwood A, McKenzie M. Investigation of cognitive screening measures in patients with brain tumours: diagnostic accuracy & correlation with quality of life. CARO 2009 Meeting. Quebec City, Quebec. Sept 29 – Oct 4, 2009. Radiother Oncol 2009;92 (Suppl2): Abstract 93. FA & SA
159. **Olson R**, Woods R, Lau J, Spears C, Weir L. Impact of internal mammary node (IMN) inclusion in the radiation treatment volume on the outcomes of breast cancer patients treated with locoregional radiation. CARO 2009 Meeting. Quebec City, Quebec. Sept 29 – Oct 4, 2009. Radiother Oncol 2009;92 (Suppl2): Abstract 105. FA & SA
160. **Lo A**, Carolan H, Aquino-Parsons C, Bottorf J, **Olson R**, Feldman-Stewart D. Decision aid for patients with ductal carcinoma in situ of the breast (DCIS) improves knowledge and reduces decisional conflict. CARO 2009 Meeting. Quebec City, Quebec. Sept 29 – Oct 4, 2009. Radiother Oncol 2009;92 (Suppl2): Abstract 108. SA
161. **Olson R**, Kosztyla R, Moiseenko V, Ramaseshan R, Carolan H, Kwan, W. Cutaneous markers used for target localization in accelerated partial breast irradiation (APBI) are strongly correlated with the underlying surgical cavity. CARO 2009 Meeting. Quebec City, Quebec. Sept 29 – Oct 4, 2009. Radiother Oncol 2009;92 (Suppl2): Abstract 119. FA
162. Kosztyla R, **Olson R**, Moiseenko V, Kwan, H. Assessment of interobserver and intraobserver surgical cavity contour variability in accelerated partial breast irradiation through the use of a representative surgical cavity contour. American Association of Physicists in Medicine (AAPM) 51<sup>st</sup> Annual Meeting. Anaheim, California, July 26-30, 2009. Abstract ID: 10586. Medical Physics 2009;36(6):2734. CA
163. **Olson R**, Iverson G, Parkinson M, Carolan H, Ellwood A-L, McKenzie M. Comparison of the Mini Mental State Examination (MMSE) and the Montreal cognitive assessment (MoCA) to a comprehensive neuropsychological assessment in patients with brain tumors. Oral presentation at the 11<sup>th</sup> World Congress of Psycho-Oncology. Vienna, Austria. June 21-25, 2009. Abstract P3.7.17. Psycho-Oncology 2009;18 (suppl. 2):S327. FA & SA
164. **Olson R**, McKenzie M, Parkinson M. Dependence of cognitive screening test results on the population being studied. 11<sup>th</sup> World Congress of Psycho-Oncology. Vienna, Austria. June 21-25, 2009. Abstract P3.7.18. Psycho-Oncology 2009;8 (suppl. 2):S327-8/ FA & SA
165. **Olson R**, Iverson G, Parkinson M, Carolan H, Ellwood A, McKenzie M. Investigation of cognitive screening measures in patients with brain tumors: diagnostic accuracy and correlation with quality of life. 2009 ASCO Annual Meeting. Orlando, Florida. May 29 – June 2, 2009. J Clin Oncol 2009;27 (suppl1;abstr e13000). FA & SA
166. **Olson R**, Brooks B, Carolan H, Parkinson M, Ellwood A-L, Roberge M-C, Martin L-A, Iverson G, McKenzie M. Sensitivity of the mini mental state examination in patients with brain tumors. Oral presentation at APOS 6<sup>th</sup> Annual Conference. Charlotte, North Carolina, USA. February 6-8, 2009. Abstract ID: 15-3. Psycho-Oncology 2009;18 (suppl. 1):S37. FA & SA

167. **Olson R**, Chhanabhai T, McKenzie M. Feasibility study of the Montreal cognitive assessment (MoCA) in patients with brain metastases. Joint Annual Scientific Meeting CARO & COMP 2007. Toronto, Ontario. October 9-13, 2007. *Radiother Oncol* 2007;84 (Suppl2):S48 (abst 166). FA & SA

(d) *Non-published Conference Abstracts*

1. Tran K, Rahal R, Louzado C, Porter G, Mitera G, Earle C, **Olson R**, Tyldesley S, Booth C, Brierley J, Halperin R, Fung S, Bryant H in collaboration with the System Performance Steering Committee and Technical Working Group. Choosing Wisely Canada® and the Development of Pan-Canadian Indicators: A New Set of Metrics to Assess the Use of Low Value Practices in Cancer Control. 2015 Canadian Cancer Research Conference. Montreal, Quebec. Nov 8 - 10, 2015.
2. **Olson R**, Munroe D, Turnbull K, Tobin P, Ward A. Prospective evaluation of unmet needs of rural cancer survivors: Comparison between four First Nations and four non-First Nations communities. Oral presentation at the 11<sup>th</sup> Conference of the Canadian Rural Health Research Society. Levis, Quebec. Oct 25 – 27, 2012. Abstract 4005.
3. **Olson R**, Wong F, Wu J, Hay J, Cheung W. Long term outcomes in squamous cell carcinomas of the head and neck: population based analysis by difference in population size of local health authorities. Oral presentation at the 11<sup>th</sup> Conference of the Canadian Rural Health Research Society. Levis, Quebec. Oct 25 – 27, 2012. Abstract 4004.
4. Howard F, **Olson R**, Bobinski MA, Parkinson M, Nurcombe W, Goddard K. Parents' perspectives of life challenges experienced by long-term survivors of pediatric brain tumour survivors. Oral presentation at the Canadian Association of Psycho-social Oncology (CAPO) Annual Conference. Vancouver, BC, Apr 25 – 28, 2012.
  1. Howard F, Goddard K, Tan de Bibians J, Pritchard S, **Olson R**, Ward A, Smilie K, Doll R, Kazanjian A. Childhood Cancer Survivors? Challenges and needs in managing their medical and psychosocial issues. Oral presentation at the CAPO Annual Conference. Vancouver, BC, Apr 25 – 28, 2012.
  2. Parkinson M, **Olson R**, Cashman R, McKenzie M, Yao J, Mackenzie G, Stephen J. Changes in quality of life, functional activities, and cognitive function from baseline to 6 months post treatment for patients with high grade gliomas. Oral presentation at the CAPO Annual Conference. Vancouver, BC, Apr 25 – 28, 2012.
  3. Ward A, Zirul C, Munroe D, Howard F, **Olson R**. Psychosocial care planning for cancer survivors: delivery challenges in rural and remote communities. Oral presentation at the CAPO Annual Conference. Vancouver, BC, Apr 25 – 28, 2012.
  4. \***Olson R**, Caron N, Olivotto I, Nichol A, Speers C, Woods R, Chia S, Davidson A, Coldman A, Bajdik C, Tyldesley S. Disparities in breast cancer screening, stage distribution, treatment use, and outcomes by population size of local health authority. Oral presentation at the 10<sup>th</sup> Conference of the Canadian Rural Health Research Society. Richmond & Vancouver, BC, Oct 20 – 22, 2011.
  5. Ward A, Zirul C, Tobin P, Howard F, **Olson R**. Cancer Survivorship Research in Northern British Columbia: Working to develop partnerships, practice, and policy. Oral presentation at the 10<sup>th</sup> Conference of the Canadian Rural Health Research Society. Richmond & Vancouver, BC, Oct 20 – 22, 2011.
  6. Lund C, Liu M, Wu J, Carolan H, **Olson R**, Schellenberg D. The Current use of stereotactic body radiotherapy for lung tumours across Canada. 14<sup>th</sup> World Conference on Lung Cancer, Amsterdam, Netherlands, Jul 3 – 7, 2011. Abstract PI.197
  7. Kosztyla R, **Olson R**, Carolan H, Balkwill S, Moiseenko V, Kwan W. Dosimetric consequences of surgical cavity contour variability in accelerated partial breast irradiation. Canadian Organization of Medical Physicists (COMP) Annual Scientific Meeting. Victoria, BC. July 21-24, 2009.
  8. Iverson G, Lanting S, Ferguson K, Roberg M-C, Parkinson M, and **Olson R**. Return to work in brain tumor patients is associated with neuropsychological test performance. International Neuropsychological Society; 2009 Mid-Year Meeting. Helsinki, Finland. July 29 – August 1, 2009. ID:623284.
  9. \***Olson R**, Parkinson M, Ellwood A-L, McKenzie, M. Community Integration Measures: Correlation with Quality of Life and Cognitive Function. Canadian Association of Psychosocial Oncology (CAPO), 2009 Conference. Vancouver, British Columbia. April 1-4, 2009. Abstract ID: B246.

10. \***Olson R**, Parkinson M, Ellwood A-L, McKenzie, M. Investigation of community integration measures in patients with brain tumors. APOS 6<sup>th</sup> Annual Conference. Charlotte, North Carolina, USA. February 7-8, 2009. Late breaking abstract ID: P2-58.

## 2. **NON-REFEREED PUBLICATIONS**

### (a) *Journals*

1. \***Olson R** and Brooks B. Understanding how brain tumours can affect your thinking abilities. Headlines, A newsletter for people who have been diagnosed with a brain tumour. Winter 2008.

### (b) *Conference Proceedings*

### (c) *Other*

1. Canadian Partnership Against Cancer. Pan Canadian Standard for Breast Cancer Surgery. 2019 Mar. (Member of Oncology Expert Panel).  
<https://www.partnershipagainstcancer.ca/topics/breast-cancer-surgical-standards/>
2. Canadian Partnership Against Cancer. Quality and Sustainability in Cancer Control: A System Performance Spotlight Report. Toronto (ON): Canadian Partnership Against Cancer; 2016 Mar. (Member of Oncology Expert Panel).  
<https://www.partnershipagainstcancer.ca/topics/quality-sustainability-cancer-control/>

## 3. **BOOKS**

### (a) *Authored*

### (b) *Edited*

1. **Olson R** & Pamela Tobin (Eds). 2012. *First Nations Cancer Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
2. **Olson R** (Ed). 2012. *Your Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
3. **Olson R** (Ed). 2012. *Breast Cancer Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
4. **Olson R** (Ed). 2012. *Colorectal Cancer Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
5. **Olson R** (Ed). 2012. *Gynecological Cancer Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
6. **Olson R** (Ed). 2012. *Lymphoma Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).
7. **Olson R** (Ed). 2012. *Testicular Cancer Survivorship Care Plan*. Prince George, BC. Northern Health (DocuSource).

### (c) *Chapters*

## 4. **PATENTS**

## 5. **SPECIAL COPYRIGHTS**

## 6. **ARTISTIC WORKS, PERFORMANCES, DESIGNS**

1. Nocturne in G major (copyright Sep 7, 2010; Reg No. 1080207)

## 7. **OTHER WORKS**

## 8. **WORK SUBMITTED (manuscripts and grants)**

- 1) Varian Medical System grant for: SIMPLIFY-SABR-COMET-PRO: **Single** vs **Multiple** fraction non-**Inferiority** trial of **Stereotactic Ablative Radiotherapy** for the **Comprehensive** treatment of **Oligo-metastases**/progression and randomization of **Patient Reported Outcome** guided intervention. \$1.2M grant requested. PI
- 2) **Appleby S, Olson R**. The Efficacy of Surgical Fixation Evaluated by the Rate of Repeat Radiotherapy in Patients with Bone Metastases. Submitted to CUREUS.

## 9. **WORK IN PROGRESS** (including degree of completion)

### **Clinical Trials in Grant Application Phase**

- 1) **CANADA-SABR-1**: **Canakinumab** in the **Adjuvant** setting for stage I NSCLC post **Stereotactic Ablative Radiotherapy (SABR)**: phase I trail
  - a. Principal Investigator submitted to Varian Medical Systems ImmunoRT and BioTargeted RT Request for Proposals
  - b. Invited proposal submitted to Novartis: asked to re-submit in spring after publication of another trial with pending results
- 2) **SUSTAIN**: **SABR Use** to reTrigger **An Immunotherapy** response in **NSCLC**: Co-Principal Investigator with Devin Schellenberg
  - a. Invited proposal being prepared for AstraZeneca
- 3) SIMPLIFY-SABR-COMET-PRO: **Single** vs **Multiple** fraction non-**Inferiority** trial of **Stereotactic Ablative Radiotherapy** for the **Comprehensive** treatment of **Oligo-metastases**/progression and the impact of **Patient Reported Outcome** guided interventions
  - a. Principal investigator submitted to Varian Medical Systems: invited to full proposal stage (submitted)
  - b. Submitted to CIHR Project Grant Spring 2022
  - c. Presenting at CCTG for endorsement
- 4) European Organisation for Research and Treatment of Cancer (EORTC) update of EORTC-Bone Metastases (BM)-22 quality of life questionnaire, and creation of a spinal cord compression sub-scale. Invited expert on this international collaboration.

### Manuscripts in Preparation

- 1) **Jiang et al**. OS results of SABR-5. Submitting to JAMA Oncology
- 2) **Olson et al**. QoL on SABR-5
- 3) **Olson et al**. SIMPLIFY-SABR-COMET-PRO protocol publication (awaiting funding decision from Varian and CIHR)
- 4) **Olson et al**. CANADA-SABR-1 protocol publication (awaiting funding decision from Novartis)

### **Names of collaborators categorized by selected major projects:**

#### 1) **EORTC Quality of Life Questionnaire creation (bone metastases and spinal cord compression)**

- Edward Chow (University of Toronto)
- Galina Velikova (Leeds University)
- Colin Johnson (University of Southampton)
- Brigette Ma (University of Hong Kong)
- Jackson Wu (University of Calgary)
- Jesmin Shafiq (UNSW Sydney)
- Kardamakis Dimitrios (University of Patras)
- Yvette van der Linden (Leiden University)



- Monica Castro
- Palmira For Arnalot (Parc de Salut Mar, Barcelona)
- Sam Ahmedzai (University of Sheffield)
- Mark Clemons (Ottawa Research Institute)
- Peter Hoskin (Royal Marsden Hospital)
- Albert Yee (University of Toronto)
- Andrea Bezjak (University of Toronto)
- Michael Brundage (Queen's University)
- Robert Coleman (University of Sheffield)
- Richard Eek (Border medical oncology)
- Marc Kerba (University of Calgary)
- Vasilis Vasiliou (Bank of Cyprus Oncology Centre)
- Kristopher Dennis (University of Ottawa)
- Jane Koh (University of Hong Kong)

## **2) Access to radiotherapy**

- Michael Brundage (Cancer Research Institute at Queen's University, Kingston)
- Jessica Chan (University of Ottawa)
- Alfredo Polo (International Atomic Energy Agency, Vienna, Austria)
- Eduardo Zubizarreta (International Atomic Energy Agency, Vienna, Austria)
- Jean-Marc Bourque (Kingston College London, UK)
- Amanda J. Sheppard (University of Toronto)
- Kristopher Dennis (University of Ottawa)
- Ben Slotman (Amsterdam UMC – Vrije University Medical Center)
- May Abdel-Wahab (International Atomic Energy Agency, Vienna, Austria)

## **3) Current or pending Clinical trials where I am the principal investigator or co-PI**

### **COMET-3 & COMET-10**

- David Palma (London Health Sciences Centre)
- Benjamin Mou (BC Cancer Kelowna)
- Devin Schellenberg (BC Cancer Surrey)
- Mitchell Liu (BC Cancer Vancouver)
- Suresh Senan (Amsterdam University Medical Centre)
- Stephen Harrow (Beatson West of Scotland Cancer Centre)
- Alison Allan (Western University)
- Rohann Correa (London Health Sciences Centre)
- Franke Schneiders (Amsterdam University Medical Centre)
- Anthony Chalmers (Beatson West of Scotland Cancer Centre)
- Andrew Warner (London Health Sciences Centre)

### **SUPR-3D**

- Fred Hsu (UBC/BC Cancer Abbotsford)
- Benjamin Mou (UBC/BC Cancer Kelowna)
- Joanna Laba (University of Western Ontario)
- Devin Schellenberg (UBC/BC Cancer Surrey)
- Alexander Louie (University of Toronto)
- Shilo Lefresne (UBC/BC Cancer Vancouver)
- Tanya Berrang (UBC/BC Cancer Victoria)

### **CANADA-SABR-1 (in preparation)**

- Dagaen Sit (UBC/BC Cancer Vancouver)
- Devin Schellenberg (UBC/BC Cancer Surrey)
- Mitchell Liu (UBC/BC Cancer Vancouver)

**SUSTAIN (in preparation)**

- Devin Schellenberg (UBC/BC Cancer Surrey)
- Mitchell Liu (UBC/BC Cancer Vancouver)
- Andrew Bang (UBC/ BC Cancer Victoria)
- Benjamin Mou (UBC/BC Cancer Kelowna)

**SIMPLIFY-SABR-COMET-PRO (in preparation)**

- Sarah Baker (BC Cancer Surrey)
- David Palma (London Health Sciences Centre)
- Benjamin Mou (BC Cancer Kelowna)
- Devin Schellenberg (BC Cancer Surrey)
- Mitchell Liu (BC Cancer Vancouver)
- Will Jiang (BC Cancer Surrey)
- Aisling Barry (Princes Margaret Cancer Centre)
- Stephen Harrow (Beatson West of Scotland Cancer Centre)
- Andrew Warner (London Health Sciences Centre)
- Quinn Matthews (BC Cancer Prince George)
- Nick Chng (BC Cancer Prince George)

**4) Clinical trials where I am a co-investigator on grant****HN.10**

- Scott Bratman (University of Toronto/Princess Margaret Cancer Centre)
- Eric Berthelet (UBC/BC Cancer Vancouver)
- James Butler (University of Manitoba)
- John de Almeida (University of Toronto)
- Irene Karam (BC Cancer Vancouver)
- Ur Metser (University of Toronto/Princess Margaret Hospital)
- Craig Pochini (Memorial University of Newfoundland)
- John Waldron (University of Toronto/Princess Margaret Cancer Centre)
- Eugene Yu (University of Toronto/Princess Margaret Hospital)
- Wendy Parulekar (Canadian Cancer Trials Group)
- Bingshu Chen (Canadian Cancer Trials Group)
- Andrea McNiven (University of Toronto/Princess Margaret Cancer Centre)
- Winson Cheung (University of Calgary)
- Marc Gaudet (University of Ottawa)
- Magda Monreal

**CAFcars**

- Philippa Hawley (BC Cancer Vancouver)
- Mark Ballard (BC Cancer Abbotsford)
- Camilla Zimmerman (Princess Margaret Hospital)
- Lyle Galloway (Tom Baker Cancer Centre, Calgary)
- Marc Kerba (Tom Baker Cancer Centre, Calgary)
- Paul Daeninck (Cancer Care Manitoba)
- Christine Whetter (Ottawa Hospital Cancer Centre)

**ACCELeRATE**

- Doris Howell (Princess Margaret Cancer Centre & Lawrence S. Bloomberg Faculty of Nursing)
- Samantha Mayo (University of Toronto)
- Monica Kryzanowska (Princess Margaret Cancer Centre & Lawrence S. Bloomberg Faculty of Nursing)
- Winson Cheung (Alberta Health Services)
- Colleen Cuthbert (University of Calgary)
- Carmen Loiselle (McGill University-Ingram School of Nursing)

- Sylvie Lambert (McGill University-Ingram School of Nursing)
- Stuart Peacock (BC Cancer Vancouver, Survivorship Centre)
- Patrick McGowan (University of Victoria, Institute of Aging & Lifelong Health)
- Judy Needham
- Melissa-Shea Budgell (University of Calgary)
- Kristen Haase (University of Saskatchewan)
- Christine Kim (Cancer Care Manitoba)
- Saeed Moradian (York University)
- Vishal Kukreti (Princess Margaret Cancer Centre)
- Janet Papadakos (ELLICSR, Health, Wellness, and Cancer Survivorship Centre)
- Joseph Cafazzo
- Kevin Thorpe
- Paul OConnell (Leukemia and Lymphoma Society of Canada)
- Denise Bryant Lukosius (McMaster University, Hamilton, ON)
- Barry Stein (Colorectal Cancer Canada)
- Kristen Haase (University of Saskatchewan)
- Geoff Porter (Dalhousie University)
- Robin Urquhart (Dalhousie University)
- Leo Salligan (NIH/NINR Bethesda, Maryland)
- Bogda Koczwara (Flinders Medical Center)
- Michael Jefford (Peter MacCallum Cancer Centre)
- Claire Foster (University of Southampton, Macmillan Cancer Survivorship Centre)
- Linda Eagen (Ottawa Regional Cancer Foundation)

#### **5) Patient Reported Outcomes research**

- Alan Nichol (UBC/BC Cancer Vancouver)
- Peter Lim (BC Cancer Vancouver)
- Scott Tyldesley (BC Cancer Vancouver)
- Shilo Lefresne (UBC/BC Cancer Vancouver)
- Erika Brown (CPQR)
- Amanda Caissie (Dalhousie University)
- Carol-Anne Davis (Dalhousie University)
- Tom Purdie (University of Toronto)
- John Kildea (McGill University)
- Michael Brundage (Queen's University)
- Lianne Wilson (patient representative)
- Michael Milosevic (University of Toronto)
- Clement Ho (BC Cancer Surrey)
- Christina Aquino-Parsons (BC Cancer Vancouver)
- Vincent LaPointe (BC Cancer Vancouver)
- Francois Bachand (BC Cancer Kelowna)
- Caroline Holloway (BC Cancer Victoria)
- Beverly Lester (BC Cancer Abbotsford)
- Regina Tam (BC Cancer Surrey)
- Susan Curtis (BC Cancer Surrey)
- Mathew Chan (BC Cancer Vancouver)
- Andrea Lo (BC Cancer Vancouver)
- Michael McKenzie (BC Cancer Vancouver)
- Avril Ullett (BC Cancer Vancouver)
- Cathy Clelland (BC Cancer Vancouver)
- Fuchsia Howard (UBC)
- Steven Tisseverasinghe (BC Cancer Surrey)
- Karen Goddard (BC Cancer Vancouver)
- Eric Tran (BC Cancer Vancouver)
- Sarah Hamilton (BC Cancer Vancouver)
- Jonn Wu (BC Cancer Vancouver)

- Eric Berthelet (BC Cancer Vancouver)

**6) Mental Health and correlation with cancer incidence and outcomes**

- Russel Callaghan (UNBC)
- Mary McLay (UBC)
- Jeremy Hamm (BC Cancer Vancouver)